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CHAPTER I 
INTRODUCTION 
Denuded skin areas (e.g., partial and ful 1 thickness burns, 
severe traumatic injury, various skin diseases) present problems with 
respect to app 1 i cation and remova 1 of convent_l_on_a_l_t_o_p_Lc_a_l_dosa,ge_foxms-.~~~~~-
With these problems in mind, a highly water soluble, flexible film for 
topical application was developed (1-3). The film adheres to denuded 
and moist skin, dissolving quickly and releasing the active ingredient. 
Both in vitro and in vivo studies were performed to evaluate 
the film. When comparing the film to commercially available topical 
antimicrobial products, ~.!_!r2,.and _L!]~~methods showed that the 
fi Jm was as effective as conventional bases for mafenide and gentamicin 
and more effective for silver sulfadiazine and silver nitrate. Also, 
preliminary stability and packaging studies indicated that the film, if 
properly packaged and stored, has marketing potential.· 
The basic unmedicated formula consists of dextran, sorbitol, 
Miranol 2 MCA Modified, and water. The major advantages of the fi Jm 
are 1) fast release rates, 2) ease of application to denuded skin without 
aggravation, and 3) lack of necessity for removal, hence no aggravation. 
However, it is extremely sensitive to moisture and elevated temperatures 
which is a major disadvantage. Excessive humidity will solubilize the 
film or make it too tacky to handle while very low humidity causes the 
film to lose its flexibility. Also, elevated temperatures remove 
moisture from the film and cause it to lose flexibility much as with 
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low humidities. 
This study was designed to evaluate further this new dosage form 
with respect to: 
1. Modification of formula to minimize moisture sensitivity. 
2. Determination of a suitable packaging material. 
3. Determination of proper storage conditions. 
4. Determination of shelf-! ife of silver sL•Ifadiazine and 
nitrofurazone dry~f~o~a~m~s~·--------------------------------------~----~ 
5. Determination of a suitable sterilizing method(s). 
Percutaneous Absorptl9~ 
Because there are many areas of controversy surrounding the con-
cept of percutaneous absorption, it is literally impossible to make 
positive statements about all of its aspects. Nevertheless, a review of 
commonly accepted generalities does serve as a reference point for a 
discussion of topical dosage forms. 
Percutaneous absorption, as defined by Rothman (4), Collaizzi 
(5), and Barr (6), is the penetration of substances from the outside 
into the skin and through the skin into the bloodstream. However, Blank 
(6,7) states that an actual definition of percutaneous absorption is not 
necessary, but rather it is more important to kno'.'l how drugs move into 
and through the skin. It is here that so many areas of controversy 
arise, i.e., routes of entry, factors affecting the rate of absorption, 
factors affecting the extent of absorption, and methods of evaluation. 
Historically, there are three periods and, hence, three schools 
of thought regarding the mechanisms of percutaneous absorption (6). 
These are 1) the period up to 1877 in which it was accepted that gases 
and volatile substances penetrated the skin easily; 2) 1877-1900 in which 
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Fleischer•s theory that the skin is impermeable to all substances pre-
dominated; and 3) 1900 to the present in which Fleischer•s theory has 
been disproved and in which much research has been done to determine the 
mechanism of and the factors affecting percutaneous absorption. This 
last period will be reviewed here. 
Routes of Entry 
11----------__,.B._.l,_,i_,..s_,..s'---(. 8) and Ha 1 i~(9J~c_La_Lm_t_r_aos_ep_Lde_rmaJ_erLtr_y_tbro_ugb_tbe, ______ _ 
.?_~ corneum to be the major route because its surface area is 100 to 
1000 times that of the transappendageal route. Shelmire (10) and Gemmell 
and Morrison (11), on the other hand, claim that the major route is via 
the skin appendages (pilosebaceous regions and sweat glands). They ba~e 
this on the observation that hair follicles possess preferential staining 
properties, perifollicular v.1heals develop, and dyes diffuse rapidly 
through the sweat glands. ~1ost investigators (4-6,12,13) agree that both 
processes are involved and that some drugs may have a greater affinity 
for one route over the other. Furthermore, Scheupl in (12) and Arita 
et~ (14) state that for drugs capable of penetrating the skin, there 
are two stages. In the initial or rapid stage, the transappendageal 
route is the primary method of entry and in the second or steady state 
stage, the transepider~al route is the major method. All investigators 
agree that before a route of entry comes into play~ the drug must first 
be released from the vehicle, transferred to the sk~n, and then have the 
ability to penetrate the skin. 
When developing a topical dosage form, the investigator is · 
essentially working with three separate entities: the skin, the dr,.~;. 
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and the vehicle. Separately, each p6ssesses certain properties which 
affect percutaneous absorption. However, in actuality, all three 
entiti~s necessarily comprises a skin-drug-vehicle system such that the 
final effect is a composite of all the sep~rate factors working together. 
Some of these factors such as hydration of skin, drug form, vehicle 
composition, and concentration of drug in the vehicle can be altered; 
others, namely those involving the anatomy of the skin p_er se, cannot 
be change~Tne purpose of the skin is primarily that of protection and 
this protective barrier must be overcome to effect percutaneous 
absorption. 
Skin factors affecting percutaneous absorption are related to 
the structure and physical/chemical properties of the skin components. 
While these properties will vary in different sites and from person to 
person, some generalities seem to hold. The major barrier to absorption 
is the s. corneum with its layer of lipids (4,8,15-18). Some feel that 
the major barrier is really between the s. corneum and the dermis 
(6,10,14). However, all agree that the major barrier is electronegative 
in nature and consists of keratin and other lipid materials. Inter-
spersed throughout the s. corneum are the various appendageal ducts which 
are filled with sebaceous or lipid substances. Thus, regardless of the 
route of entry, a drug must be partly soluble in lipids in order to 
penetrate. Likewise, undissociated drugs ~rd 11 penetrate well since 
' negatively charged drugs will .be repelled and positively charged drugs 
attracted and bound to the charged barrier (4,6,11,14). Rothman (4), 
however states that di·· and trivalent ions wi 11 penetrate to some extent 
because they are partly lipid soluble. Keratin, a sulfhydryl protein 
which adsorbs water and other polar compounds, can potentially interact 
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to hind with various drugs further complicating the predictability of 
percutaneous absorption for any drug (6). 
Other skin factors affecting absorption relate to difference in 
sites and the general condition of the skrn. For example, the forehead, 
presternal area, and the back demonstrate the greatest permeability. 
Thicker areas such as the soles of the feet and palms of the hands are 
the least permeable (8,10,19-21). Hydration from moisture and sweat 
will increase absorption because the keratin swells and becomes more 
permeable and the intercellular pores become larger (4,6,8,10,13,17,20, 
22-28). Aged skin, due to atrophy and dehydration, is less permeable 
(6,8,19,26) while young skin and skin of women show increased absorption, 
presumably because of greater hydration and thinness (8,19). These 
statements are general and individual variation must be considered. 
All of the above factors re 1 at i ng to the skin do not affect ""-~-
percutaneous absorption if the s. corneum is removed purposely or by 
disease or traumatic insult. In such instances, all drugs penetrate 
eas~ly and readily and this fact substantiates that the s. corneum (or 
zone beneath it) is the primary barrier to absorption (L!,6,10,19,20,26, 
29). 
The skin factors can be altered by removal of the skin, hydra-
tion, and emulsification. Removal, of course, is not desirable except 
in experimental conditions. Thus, it is the hydrati?n and emulsification 
aspects that product developers try to attain for topical preparations. 
Once a drug has crossed the major barrier, the lower layers of the 
epidermis and dermis offer little resistance to absorption into the 
bloodstream and subsequent pharmacological affect. The .factors which now 
enter the picture are protein binding, receptor specificity, rate of 
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metabol i~ inactivation, and rate of excretion (30). 
Two fundamental processes must occur before a topical drug can be 
effective. First, the drug mus(be released in therapeutic concentra-
tions from the vehfcle at an adequate rate and then the drug must be 
capable of penetrating the skin. Thus, the product developer must employ 
methods to evaluate the rate and extent of release and subseq~u~e~n~t ________________ _ 
absorption. Wurster and Seitz (31) have stated that vehicles which are 
porous, i.e., have a high surface area to weight ratio, will have faster 
dissolution rates and hence, faster release rates. In addition, Marcus 
~ (32) showed that the release of an active ingredient is not 
infiuenced by but is independent of the presence of other noninteracting 
drugs, since the thermodynamic activity of the drug in a vehicle is the 
only significant factor governing rate of release and absorption. Thus, 
they concluded that incorporation of two or more noninteracting drugs 
into a vehicle will allow decreased doses and side effects resulting in 
a less expensive product. 
Topical products can be evaluated by ~L!!~ and in vivo methods 
(6,7,11,21,26,27,33,34). In vitro methods include I) diffusion without 
a membrane using chemical-physical and microbiological methods; 2) 
diffusion through a membrane using chemical-physical and microbiological 
mefhods; and 3) tracer methods using radioactive substances, dyes, and 
fluorescent compounds. These methods are mainly used to evaluate 
release rates. Because the continuous phase in the diffusional media 
is aqueous, direct correlation with i_l:l_vivo results is not possible. 
Nevertheless, they do provide an excellent guide for determining the 
relative effectiveness of a vehicle (4,6,11 ,21 ,26,27,33-37). 
) 
Diffusion methods without a membrane usually employ an agar gel 
in a tube or plate. For chemical-physical methods, the agar media may 
contain a reagent that produces a color when in contact with the drug 
(e.g., salicylic acid with ferric chloride). The rate and extent of 
release is calculated based on the diameter of the color zones .in 
millimeters plotted against time. This method is simple and inexpen-
sive, is not time consuming, and does not require precautions such as 
good quantitative method and only drugs which will produce color 
react ions can be used (7, ll ,21 ,26 ,33-36). 
Microbiological diffusion employs nutrient agar medium which is 
seeded with a specific test microorganism. Release of antimicrobial 
drugs can then be evaluated by measuring the zones of inhibition. The 
diameter of the zones in millimeters is a measure of the release rate. 
This method provides a good procedure to evaluate release of anti-
microbials (7,11,21,26,33-36,38-40). Shelmire (10), Billups and Patel 
(21), Gemmell and Harrison (11), Zheutlin and Fox (41), and Scheuplin 
(12) all state that a topical antimicrobial drug does not need to 
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penetrate the skin; hence, if a microbiological procedure indicates that 
the drug is released sufficiently to inhibit microbial growth, this 
method of evaluation is very useful for these agents. However, they do 
recognize the fact that the ~skin, because of its different composition 
from an aqueous agar gel, may alter the extent of release such that 
therapeutic concentrations may not reach the site of action in vivo. 
Diffusion methods using a semipermeable membran~ such as a 
dialysis cell or agar tube covered with a membrane provide two distinct 
advantages over nonmembrane procedures. These methods l) resemble a 
8 
more true-to-life situation in which the skin is the membrane and 2) 
allow quantitative analysis of the receptor chamber using various chemi-
cal methods. For chemical-physical methods, mahy types of diffusion 
models using a membrane have been devised. Some employ very elaborate 
and sophisticated instrumentation while others are·sf~ple and straight 
forward (41-53). Membranes made of sheep bladder or isolated skin have 
been claimed to resemble true skin better; however, :me must realize 
that there is a great difference between dead and living epidermis (6). 
The basic apparatus uses two chambers separated by a membrane. One 
chamber is filled with the receptor medium (usually aqueous) while the 
other contains an accurately measured quantity of the drug product. At 
various time intervals, exact quantities from the receptor med1um are 
removed for analysis by any satisfactory method (21 ,45). The disadvan-
tages of this method are that nondialyzable substances cannot be 
evaluated and if the product chamber contains a liquid medium, drugs 
in which the vehicle is highly soluble cannot be used (43). 
For microbiological studies, an agar tube seeded with the micro-
organism is usually covered with a membrane and the product placed on 
top. Zones of inhibition are then measured to evaluate release (42). 
The advantage this procedure has over the nonmembrane method is that 
it resembles the true situation a 1 ittle more closely. Again, 
quantification is not very good. 
Of the three tracer methods, the use of radioactively labelled 
compounds is best. While dyes and fluorescent compounds are easily 
analyzed, the dye or fluorescent compound may not remain with the drug 
or thciy may alter the physical-chemical properties of the drug (6). 
However, labelling of a drug with a radioactive element can provide 
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evaluation of almost all therapeutic agents; trained personnel is the 
only major limitation. Nevertheless, the use of radioactive label ling 
is by far the best method to quantitatively evaluate the release and 
absorption of drugs (6,7, 11,21 ,26,27 ,33-36). 
The indiscriminate use of in vitro physical models and subsequent 
calculations can lead to misleading and erroneous results with respect to 
rate and extent of release (54). Chowhan and Poulsen (54), in their 
critical review, emphasize that the mathematical formulas to calculate 
release rates differ for solutions, suspensions, and semisolids. 
Furthermore, one must take into consideration the number of therapeutic 
agents present, changes in vehicle composition after application, and 
other parameters when devising an in vitro model. 
For obvious reasons, in vivo methods should be used to evaluate 
a drug product, especially with respect to absorption, metabolism, and 
excretion (6,7,11 ,26,27,33). Methods used include measuring of a 
physiological response such as vasoconstriction, analysis of body fluids 
such as urine, loss of drug from the skin surface, histological pro-
cedures, and tracer methods. While in vivo methods are preferable, they 
do possess certain disadvantages. If lower animals are used, direct 
correlation with humans cannot be made; if humans are used, expense, 
cooperation, control factors, and health hazards become problems. 
Physiological responses rely greatly on subjective evaluation 
\ 
(6,7,33) although McKenzie and Stoughton (55), McKenzie (56), and 
Vickers (57) developed acceptable vasoconstriction tests for cortices-
teroids. Washitaki et al. (18,29) used the vasoconstriction test for 
steroids and a vasodilatation test for carbinoxamine and obtained 
acceptable results for absorption. Rate of excretion, storage tendencies, 
rate of entry into and out of the bloodstream, and rate of metabolism 
must be known for tissue analysis methods; otherwise, one must estimate 
time intervals for analysis (6,7,33). Using loss of drug from the skin 
is probably the worst in vivo method of all (6,7,33). In this method, 
the drug product is removed from the skin and analyzed for drug concen-
tration. The difference at the time of application and at the time of 
removal is considered to be absorbed. However, the pitfalls in such a 
completely, the drug may have complexed with skin components and not 
been absorbed, and the quantities one is working with are so small that 
errors in analysis are likely. Histological studies are not very 
valuable from a quantitative viewpoint (6,7,33). Disadvantages of dyes 
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and fluorescent tracers were mentioned earlier along with some limitations 
of radioactive tracers. Other disadvantages of radioactive methods are 
1) autoradiography indicates if a drug has reached a particular physic-
logical site and now how the drug reached that site; and 2) urinary 
analysis only indicates that the drug is excreted in the urine and not 
the pathway into the urine. Thus, while in vivo methods are superior to 
in vitro methods, they are nevertheless only estimations and one must 
take this and specific disadvantages into consideration (6,7,). 
Stabi 1 i ty 
Whittet (58) and Schou (59) .have defined stability of a drug 
" 
product as the period of time from completion of a preparation until it 
no longer fulfills specifications of the pharmacopeia or until a 10% loss 
in potency has occurred. Thus, stability of a drug product is an 
integral part of quality control. A stable product implies that at 
~-
....;--
~--
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least 90% of the labeiled quantity of an active ingredient is in the 
product; that each dose wil I be uniform; that the product will maintain 
its appearance;. that the drug will be ~ade bioavailable; th~t the product 
is safe when used properly; and that the package and recommended storage 
conditions will not affect the product (37,60). A shelf-! ife of one 
year is considered fair while five years is considered the maximum since 
no finished product is entirely stable (60-62). Consequently, compendia! 
regulations and guide! ines for good manufacturing principles must be 
followed (59,63). 
Instability or degradation is caused by chemical, biochemical, 
and physical factors (58,59,61,64-66). Whittet (58) and Smith (64) 
reviewed these degradation processes and methods to minimize or prevent 
them. Chemical and biochemical factors include oxidation, reduction, 
and hydrol~sis reactions, racemization, specific biochemical reactions, 
and drug-package interactions. 
Oxidation is defined as the addition of electronegative atoms or 
radicals or the loss of electropositive atoms or radicals. Addition of 
oxygen or removal of hydrogen are usually involved. Air and oxygen will 
cause oxidation of drugs such as oils, fats, phenols, and vitamins. Anti-
oxidants will minimize oxidation as will removal of all air or oxygen 
from the package. The air or oxygen is usually replaced with nitrogen 
or carbon dioxide, although one must be aware of pH ~hanges caused by 
carbon dioxide. A 10° increase in temperature increases oxidation rates 
two to threefold; thus, temperature control during storage is important. 
Absorption of radiation such as ultraviolet or gamma rays also increases 
oxidation rates. Radiation sensitive drug products should therefore be 
stored in light-resistant glass containers or laminated aluminum foil. 
~-
12 
Metal ions are catalysts in oxidation reactions and these should be :: 
~ 
complexed with EDTA or the like. Moisture and pH also facilitate oxida-
tion. Thus, adjustment of pH and use of moisture impermeable containers 
--
such as aluminum laminates may be required to reduce or eliminate i--=_ 
oxidation reactions. 
Reduction reactions are defined as the addition of electropositive 
atoms or radicals or the removal of electronegative atoms or radicals. 
common as oxidation reactions ~nd usually involve the reduction by light 
of metal ions such as gold, silver, and mercury. Use of light-resistant 
containers will usually prevent these degradative reactions. 
Racemization may result in loss of potency and it obviously 
involves those drugs which have only one therapeutically active ~-
enantiomer. Racemization requires moisture and thus, moisture impermeable 
containers aid in minimizing or preventing racemization reactions from 
occurring. 
Degradative biochemical reactions can be caused by enzymes or 
microorganisms. Removing moisture, where possible, will prevent 
enzymatic degradation. Storage at low temperatures, use of preservatives, 
and protection from moisture wiil usually eliminate microbial growth and 
subsequent degradation caused by microorganisms. 
Drug-package interactions such as sorption and leaching are 
usual Jy associated with plastic containers. Selection of a noninteracting 
plastic or a different type of container will help prevent or minimize 
these reactions. 
Physical factors usually cause degradation indirectly by eliciting 
one or more of the above described chemical reactions. However, physical 
13 
factors may also directly affect drug products in a number of ways. 
Moisture wi II solubilize or cause caking of hygroscopic, effervescent, 
and deliquescent products while changes in humidity may cause these 
products to gain or lose significant amounts of moisture. Increased 
storage temperatures might cause melting of certain drug products while 
decreased temperatures lead to precipitation of biologicals or freezing 
of certain dosage forms. Further, high temperatures many times employed 
during manufacturing and sterilizing methods may degrade or even char 
certain drugs and packages such as plastics; similarly, radiation 
sterilization destroys drugs such as atropine sulfate, heparin, and 
progesterone as wel 1 as packages consisting of polyethylene and soft 
glass. Breakage, cracks, corrosion, and sealing defects of packaging 
materials cause obvious instability since the drug product is no longer ~-
protected from the environment. Finally, formulas themselves may cause 
cracking, creaming, caking, drying, and aggregation resulting in an 
unstable product. In order to assure stability, these physical factors 
must be eliminated or avoided by defining proper storage conditions, 
employing appropriate manufacturing and sterilizing procedures, selecting 
suitable packaging materials, and using stable formulations. 
While one can theoretically minimize or prevent instability 
mechanisms, the product developer must nevertheless perform stability 
tests to prove that the product is stable. The tests must be performed 
on the final packaged product in order to be valid (58,59). The most 
common experimental procedure involves storage at various temperatures 
with or without varying relative humidities; the product is then analyzed 
by various chemical or microbiological procedures as well as physical 
inspection (37,39,40,61,67-76). The method chosen for analysis is 
somewhat dependent on the nature of the drug. Chemical methods such as 
chromatography and photometry are the most common; colorimetry with 
photometry are used for drugs which form color reactions wifh a reagent. 
Agar diffusion with subsequent measurement of zones of inhibition is most 
common for antimicrobial products (39,40,59,61,67). 
The rate of degradation for most drug products follows first 
order kinetics (66,71). That is, the concentration of the drug decreases 
concentration. The basic equation for a first order reaction is 
dC 
- ~-- = kc where C is the concentration at time t and k is the first dt 
order velocity constant. In order to calculate~' the equation has to 
be changed via integration to a workable form as follows: 
J 
0 
dC 
-k.fdt = c 
InC - In c 
In C = 
log C 
k = 
or 
In c 
or 
= log 
or 
2.303 
~t 
= -k(t-0) 0 
- kt 
0 
kt 
c 
0 2.303 
log 
c 
(Eq. 1) 
(Eq. 2) 
(Eq. 3) 
(Eq. 4) 
( Eq. 5) 
where C is initial concentration, C is the concentration at timet, 
0 
0 is initial time, i~e., time zero, and k is the specific degradation 
-~-
~-
~-
constant (66,71). Once~ has been calculated, the concentration at any 
timet can be calculated. The shelf-life of a drug product can then be 
predicted from performing stability tests for relatively short periods 
of time, assuming that the product is still in a usable form and that 
concentration is a measure of activity. 
Temperature affects degradation rates as shown by the Arrhenius 
equation below (59,66,70,71 ,76,77). 
k = 
or 
log k = log A -
T 
where k =specific rate of degradation 
-1 -1 
R =gas constant (1.987 calories degree moles 
A = entropy constant 
E = energy of activation 
a 
T - absolute temperature 
(Eq. 6) 
( Eq. 7) 
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This is the reason that most stability studies are carried out at 
various elevated temperatures and then the results are extrapolated to 
room temperature. This method allows one to use relatively short storage 
periods of months as opposed to uneconomical and impractical storage test 
periods of one year or more. Results of elevated temperature studies are 
valid when the degradation is due only to thermal phenomena and not due 
to photochemical, microbiological, freezing, or other physical factors. 
For these latter instances~ long term storage studies and the use of 
appropriate order equations are required (66). 
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Packaging 
The function of a package is to preserve goods so that they get 
to the consumer for their original intended pur·pose (65,78). In addition 
to providing mechanical and environment~] protection, packaging materials 
must also be functional, inert, and available at a reasonable cost. 
Other desirable features include lightness in weight; ease of storage, 
use, and label] ing; and aestheti~ appearance. The packaging material 
shouia----cfiS()be nonfiammabie, noncorrodabie, nontoxic, odoriess, and-be 
ecologically advantageous. Availability in various sizes, shapes, and 
colors further adds utility to a packaging material. 
The common types of materials used to package pharmaceut1cals 
are glass, paper, plastics, and metals including aluminum foil. The 
manufacturer must select the most appropriate package for each type of 
pharmaceutical; all packages possess some disadvantages. While glass 
meets the main criteria, its major disadvantages are that it is easily 
broken, not as versatile as plastics and aluminum foil, and it is fairly 
heavy and bulky. Paper packages are primarily used for bandages, gauze, 
or other types of products which are not affected by atmospheric 
constituents. 
Plastics provide the most versatile type of packaging materials 
as they possess most of the suitable properties mentioned above (65,79-
84). The major disadvantages of plastics are permeation, leaching, 
... 
sorption, chemical reactivity, and alteration of structure (79-82, 84-
93). Permeation refers to the passage of gases, microorganisms, drug 
constituents, and air constituents through the package. Obviously, 
permeation can occur in either direction. Similarity of chemical struc-
ture between the plastic and the permeant increases permeability as do 
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elevated temperatures and increased atmospheric vapor pressure. A 
decr~ase in plastic crystal] inity will also increase permeation. lncreas-
ing the thickness of the plastic does not necessarily decrease permeation. 
Effects of permeation are an increase in chemical degradation rates, pH 
changes (due to carbon dioxide), changes in drug potency, and biochemical 
degradation due to microbial contamination. Leaching is defined as the 
migration of an additive from the plastic into the drug product. While 
pure plastics can exhibit leaching of components, the compounded plastics 
create the major problems. Stabilizers are the most commonly leached 
substances and cause most of the toxic reactions due to plastics. The 
pH of the drug product must be compatible with the plastic to minimize 
leaching. 
Sorption is defined as the migration of a component of a drug 
product or the drug itself into o~ onto the plastic. It is a physical/ 
chemical process and usually involves amorphous zones. Consequently, 
polar plastics exhibit greater sorptive properties than nonpolar 
plastics. Low molecular weight and ionic or electrically charged drugs 
have greater sorptive tendencies while steric and internally bonded 
drugs are sorbed less. A decrease in pH increases sorption of acidic 
drugs. If the plastic and solvent system are both polar or both non-
polar, increased sorption occurs because like systems cause swelling and 
open up sorptive passages. Increased drug concentrations and increased 
temperatures also facilitate sorption. It is the chemtcal structure of 
the drug product and plastic which determines if sorption will occur; 
all other factors only affect the magnitude of sorption. If both 
adsorption and absorption occur, the quantity adsorbed is insignificant 
with respect to the quantity absorbed. Some documented examples of 
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drug-plastic sorption are those of nylon with some antimicrobials; 
polyvinylchloride will sorb benzalkonium chloride while polyethylene 
will sorb some steroids. Low density polyethylenes have been noted to 
sorb scopolamine, pilocarpine, ouabain, and other similar compounds (85). 
Chemi6al reactivity between drug and plastic may result in 
physical changes of the plastic such as discoloration or deterioration. 
For example, benzyl alcohol, benzaldehyde, and paraldehyde will etch 
and dissolve polystyrene; certain oils will dissolve polyethylene; 
fluorinated hydrocarbons attack polyethylene, polystyrene, and polyvinyl-
chloride. The choice of the right plastic polymer will help avoid such 
problems (85,87,89). Alteration is usually due to these four drug-plastic 
interactions. For example, gases or vapors may cause swelling or 
collapsing of the package depending on which way the gas permeates. 
Heat, UV light, ethylene oxide, and other sterilization procedures may 
also deteriorate some plastics (85,87,89). Provided no contraindications 
with respect to these disadvantages are present, Estevez et al. (81) 
state that plastics should be used when: 
1. Plastic offers particular functional advantages. 
2. The drug product is so expensive that breakage must 
not occur. 
3. The drug product is so dangerous or obnoxious that 
breakage must not occur. 
4. The risk of breakage is high and the con$equences of 
broken glass are ~ery dangerous (e.g., in nurseries, etc.). 
5. Mailing and transportation costs are based on weight 
and thus, are high. 
6. Use of printed containers is advantageous. 
7. Specific shapes are desired. 
8. Plastic is the only practical choice. 
""'=-
= ~ 
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Drug manufacturers must ascertain the potential of drug-plastic inter-
actions as well as the stability aspects of the plastic itself (81). 
While many authors have cited some specific drug-plastic interactions 
(62,79,80,85,88-92,94-96), any time a new drug-plastic system is used, 
~-
storage of the packaged drugs at various conditions and subsequent 
analysis must be done (62,87). Stability of drug products has already 
been discussed. 
To determine changes in the plastic, impact resistance, average 
tensile strength, average ultimate elongation, melt Index, infra-red 
analysis, and moisture permeability tests must be performed before as 
If 
well as after storage. In addition to these tests, physical inspection 
of the package with respect to rupture and/or swelling must be done to 
determine stability. ~-
Toxicity due to plastics appears to have been overestimated (81, 
86,90). However, toxicity can occur directly from actual contact with 
the plastic as well as indirectly via contents of the package. The most 
common acute toxic reaction caused by pure plastics is sensitivity; 
however, it is rare. Compounded plastics as used in catheters or other 
internal devices, can cause thrombosis, embolism, thrombophlebitis, and 
necrosis. Also, if the plastic is contaminated, septicemia and 
bacteriuria may occur. In addition, such devices have been known to 
break-off in the body and cause physical damage to the circulatory system, 
urinary tract, etc. Direct toxicity is usually due to stabilizers present 
in the plastics. Chronic toxicities are manifested chiefly by neoplasms. 
While not yet seen in man, various malignancies in other animals have 
been caused by plastics such as polyethylene, polyvinylchloride, nylon, 
and others. Various mechanisms have been suggested as to the 
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carcinogenicity of plastics (90). Indirect effects are usually due to 
plastics used as occlusive dressings where excess percutaneous absorption 
may occur. Also, solutions and/or blood stored in plastics may leach 
some of the harmful additives (90). 
Metals are used mainly for packaging aerosols and nuclearpharma-
ceuticals. In addition, laminated aluminum foil, because of its 
impermeability and light weight, is the package of choice for moisture 
gamma-radiation (83,84,98,99). Laminates, such as lacquers, vinylchloride, 
and polyethylene, are used to provide a heat seal. Because polyethylene 
adds mechanical support, it is the most widely used (100). The seal 
should be peelable so that sterile products can be removed aseptically. 
Hughes (100) adds that the heat seal is the most common cause of 
defective aluminum foil packages. The sealing process must be tested by 
immersion in water for five minutes and then inspecting the package 
visually for moisture. Hughes also states that laminated aluminum is 
the most moisture impermeable flexible package. To assure impermeability, 
at least 0.018 mm and preferably 0.03 mm gauge foil should be used 
{83,100). Often the outside of the foil is coated with cellophane to 
increase impermeability and add an aesthetic sheen to the package (101). 
In general, laminated aluminum foil meets almost every suitable property 
cited. 
Sterilization 
Sterilization is a process by which all microorganisms are kil Jed 
or removed such that they are no longer detectable in standard culture 
media in which they are known to grow {102,103). Bowman (49) adds that 
~-
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sterilization does not necessarily kill all microorganisms but rather 
reduces them in number such that they cannot multiply in favorable media 
and thus, the sterilized article is made safe for use. The common 
sources of contamination are raw materials, equipment, containers, per-
sonnel, environment, and the user (102). 
There are numerous methods of sterilization. Boucher (I 08) 
defines disinfection as a method which destroys disease causing micro-
organisms; only when it becomes powerful enough to kill all types of 
microorganisms, is it a sterilizing method. The AOAC test established 
by the USDA is used to determine if a disinfectant is, in fact, a 
sterilant. 
The various sterilizing methods possess specific advantages and 
disadvantages with respect to usefulness. The properties of the articles 
to be sterilized and the properties of the sterilant will determine what 
method is best (102). Some generalities apply to all sterilization 
methods. These include testing, certification, and adequate record 
keeping of sterilization cycles. In addition, quality control must be 
employed using suitable indicators and testing media as well as strict 
( 
adherence to procedural and operational instructions. The proper train-
ing of personnel is imperative (103,105,109,110). 
Autoclaving is an easy and effective sterilization method withe 
toxicity or residues. It is easily_ controlled and measured and is 
economical after initial installment. A large majority of articles can 
be sterilized with this method. However, oils, greases, powders, and 
similar substances cannot be penetrated by steam and sharp instruments 
are du 11 ed. A 11 air must be removed from the chamber and some drugs are 
deteriorated by high temperatures and steam. The mechanism of action is 
I ~ 
~= 
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enzyme inactivation and protein denaturation. In general, autoclaving 
is the best method of sterilization when it can be used (103,108). 
A dry heat oven with air circulation becomes a very'useful method 
of sterilization. Temperatures of 160°- 170° for 1-3 hours will kill 
most microorganisms and destroy pyrogens (103). Again, enzyme inactiva-
tion and protein denaturation are the mechanisms of action. The major 
advantages of dry heat are that instruments are not blunted or corroded, 
11-----~am.:J~o-r--1-g-;---powders, and steam sensiTive drugs can be sterilized. Its 
disadvantages are long exposure times and high temperatures (103). 
While not practical for hospitals or laboratory use, irradiation 
with x~ or gamma rays is a very effective means of sterilization (98,99, 
103,108,111). Sterilization occurs directly via ionization and 
indirectly via diffusion of radicals (108,111). Gram negative bacteria 
are very sensitive to radiation while viruses, yeasts, fungi, and spores 
exhibit varying degrees of resistance. Major sources of these steril-
izing rays are Co-60 and Cs-137 (99,108). The advantages of irradiation 
sterilization include quality control as to number and energy of the 
radiations; the products do not become radioactive; it is effective 
against most microorganisms; and it penetrates most packaging materials. 
Its disadvantages are that trained personnel are required and some 
packages are destroyed. Factors affecting radiation sterilization are 
presence of oxygen or other protective compounds, physical state and 
water content of the microorganisms, and temperature (108). B. pumilu~ 
and B. stearothermophilus are the recommended biological indicators 
(104,108,109,111). Radiation is the best method to sterilize topical 
drug products, especially enzyme preparations, and is the best method to 
sterilize laminated aluminum foil packages as mentioned earlier. Dietz 
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(99) has reviewed the aspects of contract sterflization and discussed the 
many advantages it possesses, including relative inexpensiveness. It is 
best to sterilize the finished, packaged product (98,99). 
Ultraviolet radiation photons of high energy kill microorganisms 
via DNA inhibition (112). Maximum bactericidal effects occur at 240 to ;;;-
280 nm; 253.7 nm is used commercially because most UV lamps emit 95% of 
radiation in this latte~ wavelength (108,112). Applications are limited 
th_a_t-ti\i--rays have poor peneiTarl ng power and-1:hus, can on lyoe used 
on clean surfaces with simple geometry and at short distances (108). 
Also, certain plastics polymerize on exposure to UV rays (108,112). Its 
major use is in the sterilization of room air for which it is highly 
effective (113-116). 
Fl ltration employs the use of screen filters which have a pore 
size of 0.22 microns or less (117). These filters are made of cellulose, 
synthetic polymers, or silver films. The pore volume constitutes approxi-
mately 70-85% of the filter diameter so that high flow rates are achieved 
(118). The filters are inert, maintain their original integrity, do not 
impart fibers or debris, possess minimum adsorption, and are resistant 
to water, dilute acids, and hydrocarbon solvents. They do not affect 
the pH of filtered solutions and are very useful for sterilizing drug 
products which are sensitive to· heat or cannot be sterilized by other 
methods. Disadvantages are that the filters are not resistant to 
corrosives such as nitric acid, sulfuric acid, sulfur, and cyanide so1u-
tion. Silver membranes undergo the usual silver reduction reactions 
(118). 
Ethylene oxide {EtO) gas was first used as sterilizing agent in 
1933 (119). Because of its high solubility, it penetrates most porous 
materials (103,108,120-122). When conditions are appropriate, EtO kills 
all microoorganisms via alkylation of sulfhydryl) amino, hydroxyl, 
carbonyl, and phenolic gro~ps present in the organism (108,121,123-127). 
This alkylation, shown below, causes irreversible metabolic changes in 
the organism. 
H H 
L~ 
g_ 
ii 
s---
~-
H2c~cH2 + protein-SH ~'=~~'1~ protein-S-C-C-OH ~~~~'~-~~~~~~~~~~HH~~~~-
EtO viable organism killed organism 
Dessicated occluded spores provide protection from EtC's lethal effects 
(112, 124); however, if articles are cleansed of debris, usually the 
occlusivity is interrupted and the organism becomes susceptible (125). 
Sykes (1 12) stated that the two most resistant bacteria to ethylene 
oxide are Staphyloc~ccus and B. anthroides and yet, at a concentration 
of 500- 750 mg/L of EtO for 6-7 hours, these organisms were killed. 
Because EtO is explosive, it is usually diluted with carbon dioxide, 
nitrogen, or Freon 11 or 12 (103~108,112,122,128). These diluted mix-
tures require longer exposure times than pure EtO (128). The conditions 
of an EtO sterilization cycle vary with dilutions. While different 
conditions have been used successfully, all investigators state that 
certain procedures will afford greatest efficiency (103,105,108,112,120-
124,128,129). Elevated temperatures, i.e., 50°, relative humidity of 
30-80%, exposure times of !1-12 hours, and EtO concentrations of 450 mg/L 
to 1000 mg/L are recommended. In addition, an aeration time of 100 hours 
\ 
at room temperature or 8-12 hours at 50° should be used. Further, vacuum 
for undiluted EtO and positive pressure for diluted EtO are recommended. 
i; __ 
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The main advantages of EtO are that it is effective against all 
microorganisms; the procedure is simple and causes little damage to 
articles. Further, it is useful for products sensitive to excess heat 
or_steam; it penetrates most packages and is relatively inexpensive. 
Its disadvantages include explosiveness, long exposure and aeration tlmes 
as well as toxicity. Direct toxic effects of EtO, its residues, and its 
two commonest derivatives, ethylene glycol (EG) and chlorohydrin (EC) 
have received much attention and some disagreement occurs among 
researchers (103,108,112,120,127,130-137). The general chemical 
reactions forming these derivatives are shown below (108,127). 
+ H ce~CH2 21 I 
HO OH. 
EtO ~later EG 
+ HCl 
EtO EC 
These derivatives, like EtO itself, wi 11 dissipate from the article when 
allovJed to aerate. Aeration time is dependent on the type of package 
being sterilized (103,108,112,120-122,128,138). The greater the so1u-
bility of EtO in the package, the faster the steri1 ization, but also the 
longer the aeration time req~ircd (120-122,134). To determine residual 
levels of EtO and its derivatives, many methods have been used (119,132, 
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134,137,138). Kaye (139) emphasizes that because of these toxic residues, 
overtreatment for "safety margin11 purposes must not be used with EtO 
sterilization. 
Boucher (108) has discussed various ~iscel laneous methods of 
sterilization. Included in his discussion are the·use of B-propiolactone, 
alkylanized glutaraldehyde, acid glutaraldehyde, iodine, formaldehyde 
and others. All have specific applications but because of various dis-
ad'ITCffftages, they are not commonly used to sterilize pharmaceuticals. 
Once a method of sterilization has been chosen, both indicators 
and sterility testing must be employed. Bruch (107) has stated that 
two basic types of indicators are available, biological and chemical/ 
physical. He claims that biological indicators are the only indicators 
which can evaluate or integrate all sterilization parameters and that 
they provide the best assurance of sterility. Commonly used organisms 
as biological indicators are B. subtilis var. niger for wet and dry heat 
(104); !:.~milus and B. stearothermophilu~ for gamma irradiation (lah, 
108,109); and~ .. stearothermophilus for EtO (104,105,109,140). 
B. stearothermophilus is one of the commonest biological indi-
caters available commercially (109,140). Brewer and Arnsberger (140) 
have developed a method which combines a chemical indicator and the 
biological indicator, B. stearothennophilus. The chemical indicator, 
4-(4-nitrobenzyl·) pyridine, forms a blue color when exposed to EtO . 
..... 
Thus, 4-(4-nitrobenzyl) pryidine will indicate if EtO has permeated the 
package and B. stearothermophilus will indicate if the concentration was 
sufficient to sterilize the article. The chemical reaction for 
4-(4-nitrobenzyl) pyridine and EtO is shown below. 
- -; -- _:--~ 
~--
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pyridine 
Sterility testing involves culturing samples of each lot in 
suitable media. Either direct inoculation of the sample into the media 
or solubilizing the product, filtering it, and then culturing the filter 
may te used (102,104). The main purpose of testing is to create optimum 
conditions for microbial growth; thus, suitable media must be employed. 
The USP XVI I (141) recommends Fluid Thioglycollate Medium (FTM) and 
Sabouraud 1 s Media. However, Soybean Casein Digest (SCD) has replaced 
Sabouraud 1 s Media in the USP XVIII (106). Sterility testing is not an 
absolute guarantee since cultivation of all viable microoorganisms is 
impossible, sampling is many times inadequate, and failures in technique 
may occur (104). If a product contains an antimicrobial or preservative, 
it must be inactivated prior to testing (142). Abdou (143) has compared 
th~ appropriateness of seven test media. His results showed that 
peptone liver digest broth, peptone 1 iver digest agar, and dithionite-
thioglycollate media were superior with respect to cultivating all types 
of microorganisms. If more concurring data is accumulated, these media 
may v.Jell replace the more common ones. All regulations regarding 
sterility testing allow for accidental contamination (104). 
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When performing sterility tests and using biological indicators, 
both positive ahd negative controls should be used (142) and one must 
always recognize that none of these methods are an absolute guarantee 
that the entire load is sterilized (102,105,107,110,121,124,128). 
Review of Objectives 
A water soluble, flexible dry foam was developed for application 
to denuded skin areas (l-3). The foam demonstrated therapeutic eq-"<u-'-iv.,_.a..._- ____ _ 
lence when compared to commonly used ointment bases. Hm"Jever, the foam 
was physically unstable as deterioration and/or loss of flexibility 
occurred after storage at various conditions. 
This study will improve the stability of the dry foam by modifying 
the original formula, determining a suitable packaging material, and 
defining optimum storage conditi~ns. Medicated dry foams using nitro-
furazone and sliver sulfadiazine~ill be prepared, packaged, and stored 
at various conditions; in vitro release will be compared before and after 
storage to determine stability with respect to shelf-life. In addition, 
the foam will be rendered sterile since it is best to use sterile 
products on open wounds. 
CHAPTER II 
EXPERIMENTAL 
All chemicals and materials and all equipment used in the 
experimental procedures are 1 isted in Tables I and I I respectively. 
Preliminary Studies 
At the onset, it was assumed that the original formulation (1) 
could be satisfactorily packaged in plastic bags. Thus, the following 
formula was manufactured: 
Dextran 
Sorbitol 
Miranol 
Water 
'16. 00 g 
10.40 9 
0.20 g 
76.00 g 
The dextran was added to the water and heated on a water bath to 70°. 
The sorbitol solution was then added and the solution poured into a bowl 
containing the Miranol. Using an electric kitchen mixer, the solution 
was whipped for ten minutes producing a light, white foam. The foam was 
then spread onto four Teflon coated metal sheets, each fitted with two 
1211 x 1-1/2 11 x 1/1611 plexiglas strips for control of uniform spreading. 
Prior to spreading the foam, a light coat of silicone was applied to the 
sheets to aid in removal of the final dry foam. The pans were then 
placed in a horizontal laminar flow hood with an air velocity of 
110 ft/mln. and turned every fifteen minutes. After one hour of drying, 
the dry foam could be easily removed from the pans with a rubber spatula. 
An oven set at 40-45° would allow faster drying, but because temperatures 
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TABLE I 
Ch~~icals and Materials Used in the ExperL~ental FJ:>ocedurer 
Na.~e 
Dextran, M.W. 73,200 
Sorbo Solution, 70% 
l1iranol 2MCA Modified 
Glycerin 
Silicone, D.C. 556 
Nitrofurazone Powder 
Nitrofurazone Cream, 0.2% 
Silver Sulfadiazin~ Powder 
Silver Sulfadiazine Cream, i% 
Unibase Cream 
Calcium Chloride 
Ethylene Oxide, 100% 
B. subtilis spores 
Ethylene Oxide Indicator 
Staphylococcus aureus 
Antibiotic Medium 2 
Fluid Thioglycollate Medium 
Soybean Casein Digest Hedium 
I ~~m~' I "iiT'illil 'Y 
I 
I 
I 
.I 
I 
Lot No. or Other I 
... Identifying .Xarks .... j 
34C-1350 
606K6 
9209t172ST 
3022002 
6 
E96n9 
708900 
7115 BS 
E4547 
PK 310 
Drierite 
EPA #7128-1 
Attest 
Index 
A.T.C.C. #25293 
525075 
575191 
614363 
" 
Man uf aJ~turer 
I 
Sigroa Corporation, St.ILouis, l1o. 
The Ruger Chemical Co.!, Irvington, N.J. 
The ~1iranol Co., IrvinJ~ton, N.J.· 
Colgate-Palmolive Co., INew York, N.Y. 
The Ruger Chemical Co.d Irvington, 
Eaton Loboratoriea, Notioh, N.Y. 
Eaton Laboratories, Norlwich, N.Y. 
Harion Laboratories, Kansas City, 
Marion Laboratories, Kjnsas City, 
P~ko-Davia Co., Det~+· Mich. 
1-l.A. Hammond Drierite Co., Xenia, 
3M Co., St. Paul, Minn. 
3M Co., St. Paul, Minn. 
3M Co., St. Paul, Minn. 
N.J. 
Mo. 
Mo. 
Ohio 
~-~ 
I 
I· 
I 
I 
A~erican Type Culture Ciollection, 
Difco Laboratories, Det:!:'oit, Mich. 
Difco Laboratories, Detj::>oit, Mich. 
Difco Laboratories, Dettoit, Hich. 
Rockville, Md. 
. I 
I 
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I 
I 
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TABLE II 
Equipment Used in the ExperL~antal Procedures 
I . I Equipment I _::nufacture,, 
I Seal-A-Heal Bags J Dazey Corporation, KanJas I I City, Mo. 
j Heat Sealer I 
I Cenco Moisture Balance / 
I ~=~nated ~~ne® Foil :ags I 
1 .uaiT.lnated AJ.UmJ..nurn Fo1.l oags l 
I Fisher-Lilly Zona Reader 
I Ethylene Oxide Chamber, Model 200 
I 
I 
Ethylene Oxide Aeration Chamber, Model 33 
Airguide. #605 Relative Hu~idity Indicator 
, 
I Springfield #552 Relative Humidity Indicator 
I 
Dazey Corporation, Kanslas City, Mo. 
Central Scientific Co. ,I Chicago, Ill. 
Eli Lilly Co. , Indianap:olis, Ind. 
The Rexham Corporation,! Charlotte, N.C. 
Fisher Scientific Co., :!?ittsburgh, Pa. 
3M Co., St. Paul, Minn. 
3i'! Co., St. Paul, Minn. 
Ail,~'f...!ide I~s"trt:rr;en't Co. i, Chicago, 111. 
Springfield Instrument J~o. , Hackensack, 
I 
N.J. 
w 
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in an oven are not uniform, uneven drying would occur causing the foam 
to be too dry in some areas and still be wet in others. Small strips 
app~oximately 50 x 30 ~n were cut, weighed on an analytical balance, 
packaged in Seal-A-Meal Bags, and heat sealed. The packaged samples were ~-
then stored in a refrigerator (5°; R.H., 55·60%), a freezer (-5°; R.H., 
75-90%), and at room conditions (22°; R.H., 40-50%). On the day of man-
ufacture, moisture content was determined by weighing six samples on the 
{\-------.an-a-1-yth:<rl-b-cd-alTc-e-;-0-.yirrg-fhem to constant weight at n 1 nety vo 1 ts on 
the Cenco Moisture Balance, and then calculating moisture content 
according to the loss in weight. It was assumed that any loss in weight 
was due only to water loss. Average moisture content on the day of 
manufacture was found to be 12.7%. Four samples were removed and 
analyzed for moisture content after one, two, three, four, six, eight, 
and twelve weeks of storage. Table I I I summarizes the results of the 
above procedure. The changes in moisture content indicated that the 
plastic bags were permeable to moisture and showed that changes in 
relative humidity could cause the dry foam either to lose or to gain 
moisture. Maintaining approximately a 10% moisture content is advisable 
to yield a flexible, nonsticky product (1). That is, a significant loss 
of moisture causes the foam to lose flexibility while a significant gain 
causes the foam to become so moist that it adheres to the package or 
dissolves when touched. The data in Table I II indi~ate the variability 
~ 
of moisture contents of the dry foam packaged in plastic. These changes 
not only show that plastic alone is not a suitable package, but also 
confirms the necessity for a moisture impermeable package. Further, the 
data indicate the need to establish optimum storage conditions with 
respect to. temperature and humidity. 
TABLE III 
Average Per Cent Moisture Content* of Unmedicated Dry Foam in PlasTic Bags 
Room Conditions §efrigerato::::-
(22°; R.H., 40-50%) (+5 ; R.H., 55-60%) 
Duration of 
Storage 
1 week 12.6 14.2 
2 weeks 13.9 14.6 
3 weeks 14.0 14.5 
4 weeks 12.6 13.2 
6 weeks 13.4 12.8 
8 weeks 11.3 12.2 
12 weeks 12.7 16.0 
MEAN 13.0 16.3 
*Average moisture content of 6 samples on day of preparation was 12.7% 
'~~~liil'!'"llr'lllil'f ' 'I I' ·'1111''"'1' 1'"11' 1'''"!'1 
(-5 ; R.H., 75-90%) I 0 Freezer 
16.2 
17.6 
Deteriorated 
Deteriorated 
Deteriorated 
Deteriorated 
Deteriorated 
16.9 
w 
w 
I' u!: ~1 :;rrn: 1 .• :rpr .1 '· iJ:;~mr::rrr~:: .::n!~.:trJ~:r:i::J!:;:~ . ·f ~ 1n :::_u: . Fr- --· 
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Acceptability of a packaging material, based on changes of mois-
ture content in percent, was arbitrarily set as below. 
1. Excellent: < 0.5% change; acceptable 
2. Good: < 1.0% but > 0.5% change; poss. acceptable 
3. Fair: < 2.0% but > T.O% change; not acceptable 
4. Poor: > 2.0% change; not acceptable 
Lining the plastic bags with waxed and parchment papers, as well 
l------'as_tJsJ_n_g_d_o_u.b-1-e-p-1-a--S-t=-i-e-b-a-s-s~,-d-i-d~R-e-t-i-n-l\3-F-0-V-e---:-J3~1-y-s-i-e-a-1-s-t-a-b-i-1-i-t-y-e-f-t-h-e------_ 
foam (see Table IV). Rather than search for a moisture impermeable 
plastic, it was decided to seek alternate packaging materials. Carre-
spondence with a number of packaging manufacturers and users suggested 
that laminated aluminum foil bags would meet the moisture impermeable 
requirements most satisfactorily. It was also decided to modify the 
~-
formula in an attempt to decrease moisture loss by adjusting humectant 
content. 
Laminated aluminum foil bags were secured from Eli Lilly and Co. 
These bags had a 0.00075 inch thick aluminum foil sandwiched between an 
outer coat of eel lophane and an inner coat of high density polyethylene. 
As implied earlier, ideally, the dry foam should be flexible, 
easy to handle, i.e., does not stick to package or to hands, and be 
soluble on moist· skin. These parameters apply at the day of manufacture 
as wel 1 as after storage at various temperatures and humidities. A 
lesser but nevertheless significant criterion is the pore size. The dry 
foam is a very porous formulation and any changes in pore size after 
storage would indicate deterioration of physical structure. 
Nitrofurazone 1% and silver sulfadiazine 1% dry foams were pre-
pared using three different concentrations of glycerin in addition to 
''"' ""'' ===~-~'/"""'--~----------~------
TABLE IV 
! 
' 
' 
I 
Average Per Cent Moisture Content of Unmedicated Dry Foam : 
in Plastic Bags with Liners 
r Duration of Room Conditions Refrigerator 0 Freezer I 0 Oven I 
Storage (22°; R.H., 40-50%) (+5°; R.H., 55-60%) (-5 ; R.H., 75-lO%) (37 ; R.H., 25%) I 
A B. C A B C A B d A B C 
' 1 week 6.4% 6.7% 7.1% 8.5% 8.1% 8.9% 9.3% 8.0% 9.4% 4.4% 4.3% 4.7% 
2 weeks 6.3% 6.0% 6.3% 9.0% 8.6% 9.3% 10.6% · 8.9% · 10.5% 3.1% 3.3% 3.3% 
' 
3 weeks 7.5% 7.3% 7.3% 9.2% 9.1% . 9.2% 12.6% 10.5% 11.r% 5.2% 5.2% 5.3% 
4 •• ~. 6,61 6.4% 6.71 9.6. 9.2. 9.41 15.31 12 .•• 13.rl 3.91 3.91 3.9% . 
MEAN 6.7% 6.7% 6.9% 9.1% 8.8% 9.2%-'-~2.0% 10.1% ~~·I' 4.2% 4.2% 4.3% 
A = bags lined with waxed paper; average moisture content of 12 samples on day of prepi3.I'ation = 9. 3% 
· B = bags lined with parchment paper; ave. moisture content of 12 sampies on day of pre!)aration = 9. 0% 
I 
C = double bagged; average moisture content of 12 samples on day of preparation = 10.1~~ 
'!111~''m'iil'n , I r 'I' 1.11. 1 ,,~.,!1 1 "PF ,:,J.rlm':'IF :~1 ::pt::Lpr:. 
w 
•...n 
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sorbitol. Also, the original formula without glycerin was manufactured 
for comparison. Moisture content and subjective evaluation of gross 
physical properties, i.e., flexibility, stickiness, dissolution time, 
porosity, were determined on the day of manufacture. Samples of each 
~-
dry foam were then weighed, packaged in the foil bags, and heat sealed. 
Three samples were stored for one week at the following conditions: 
The various formulas for nitrofurazone dry foams are listed in Table V 
and for silver sulfadiazine, Table VI. Table VI I lists the moisture 
content and subjective evaluation of the nitrofurazone formulas on the 
day of manufacture and after storage. Table VI II su~1arizes these data 
for silver sulfadiazine foam. 
Because these formulas (see Tables V and VI) were too sticky, 
three additional formulas with decreased concentrations of glycerin were 
prepared and compared to the original. Additional storage conditions of 
room temperature, refrigerator, .. and a laboratory oven were included in 
the stability studies. Because laminated aluminum foil bags maintained 
satisfactory moisture content (see Table VII and VIII), moisture content 
-
determination was not done in this part of the study. The additional ~ 
fonnulas are listed in Table IX for nitrofurazone and Table X for silver 
sulfadiazine. The subjective evaluations are summarized in Tables XI 
and XI I respectively. 
These preliminary tests indicated that modification of the 
original formula with glycerin in concentrations greater than 0.19% wet 
weight, i.e., formulas II-VI of nitrofurazone and silver sulfadiazine, 
i·ll"C!l'll '"""'-~'""-'""-~--'-------------------- ---~-~--r--~-~- ~····.,-------~=== ...... -----
TABLE V 
Composition of Original (I) and Modified Formulas (II-IV) of 1% 
Formula Number Water Dextran Sorbitol Glycerin 
I 28.5* 6.0 3.9 
II 27.6 6.0 3.9 0.94. 
\' 
III 27.8 6.0 3,;9 0.75 
IV 28.1 6.0' 3.9 0.38 
* Quantities are listed in grams. 
TABLE VI 
Nitrofurazone! Dry Foam 
I 
MiraAol Nitrofurazone 
I o.or 
o.or 
o. 0715 
o. 0715 
0.10. 
0.11. 
0.11 
0.11 
Composition of Original (I) and Modified Formulas (II-IV) of 1% Silver Sulfadii3.zine Dry Foam 
, . I 
Formula Number Water 
~ 
I 28.5* 
\ 
II 27.6 
III 27.8 
IV 28.1 
... . . . . . . 
* Quanti~ies are l:i,sted, in grams~ 
I j1Wffi1ml'"··.-.mmllll~ I. 
'111111\ilil.l.l 111!1111 
Dextran Sorbitol Glycerin 
6.0 3.9 
6.0 3.9 0.94 
6.0 3.9 0.75 
6.0 3.9 0.38 
'I ! I i I 
. I Miran~>l 
I 
o. 0751 
o. 07~1 
0.071 
0.07S 
..... I· 
.:I 
Ag Sulfadiazine 
0.10 
0.11 
0.11 . 
0.11 
:m,r .1 :'n .I: 'nmr ~w 
w 
-.....! 
. .. ·!·1:11. .: .. i L.:·:-' ~-·1,1\ 
----------~--~~~-"------~--~~ -~~ 
Formula A 
No. 
I 10.0% 
II 9.8% 
III 9.1% 
II 
IV 9.3% 
I 
TABLE VII 
Average Per Cent Moisture Content and Gross Physical Appear.:'fce (GPA) 
After Sforage of Nitrofurazone Formulas in Foil Bags* Before and 
B c GPA on Day of GPA in Freezer 
I 
G~A in Dessicacor 
Preparation (-!f; R.H. 75-90%) (2f>; R.H. S-6%) 
10.8% 10.2% Flexible Unchanged I 
Stuck to bags 
Dissolved on moist Slight loss of 
skin in 15 sec. flexibility 
Not sticky Other propercies 
Even porosity unchanged 
9.8% 10.1% Very flexible Increased I Great increase in 
Dissolved on moist porosity porosity 
skin in 15 sec. Other properties Stuck to bags 
Sticky unchanged Other properties 
Even porosity unchanged 
8.9% 9.3% Same as II Same as II· I I Same as II 
9.0% 9.4% Less sticky than Unchanged Slightly stuck to 
II and III bags 
Other properties Slight loss of 
same as II & III flexibility 
Other properties 
unc:hanged 
, m~.~''"m'iil'r~ 'I I 1.•;•1· [.: I 
I 
w 
6o 
... II .. '· 
"I 
·-------------
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Formula I 
No. 
A B 
TABLE VIII 
Average Per Cent Moisture Content and Gross Physical Appearlmce (GPA) 
of Silver Sulfadiazine. Formulas·· in Foil··Bags 1'•··Before--and··Afi:er Storage 
c GPAon Day of . 
. Preparation ... 
GPA in Freezer ~~; GPA in Dessicator 
..(-5°; R.H. 75-90%) 1 .(22°; R.H. 5-6%) 
' ' 
I I r-I 10.9% I 9. 4% Flexible Unchanged 1 
Dissolved on moist ! 
Slightly stuck to 
bags 
Increased porosity 
Slight loss of 
flexibility 
II 10.5% 10.4% 9.7% 
)II .. J. 9.3% 9.0% 9.1% 
IV 8.8% 8.8% 8.7% 
skin in 15 sec. j' 
Not sticky: 
Even porosity 
. . I . . . . . . 
Very flexible 
Dissolved on moist 
skin in 15 sec. 
Sticky 
Even porosity. 
SaJne as II 
Less sticky than 
II and III 
Other properties 
same as II & III 
Increased 
porosity 
Increased 
stickiness 
Other pr·operties 
.. unchanged . 
Same as II 
tJnchariged 
II 
lr 
*Eli Lilly and Co., Indianapolis, Indiana 
',lnmr:·iiT'I~~n , I ,,. IiI I 
Other properties 
uncha;::.ged 
Great increase in 
porosity 
Stuck to bags 
Loss of flexibility 
Other properties 
unchanged 
Same as II 
Same as I in dess. 
except ·still sticky· 
J:lJ:.J 
! I '·"n ,,: 
·W 
\.0 
.. _n: ... 
TABLE IX 
Composition of Original (I) and Additional Formulas (V-VII) of 1% 
Formula Number Water Dextran Sorbitol Glycerin 
I 28. 5)'< 6.0 3.9 
v 28.2 6.0 3.9 0.30 
VI 28.4 6.0 3.9 0.15 
VII 28.4 6.0 3.9 0.075 
-
* Quantities are listed in grams 
TABLE X 
Nitrofurazone 
Mtcl 
o.r75 
o.r75 
0.075 
I 
0.075 
I 
Dry Foam 
Nitrofurazone 
0.10 
0.10 
0.10 
0.10 
Composition of Original (I) and Additional Formulas (V-VII) of 1% Silver Sulf,diazh:e Dry Foam 
Formula Ntunber Water Dextran 
I 28.5* 6.0 
v 28.2 6.0 
VI 28.4 6.0 
VII 28.4 6.0 
* Quantities are listed in grams 
'~~~~" 'iir'illil'~ r. I 
Sorbitol Glycerin 
3.9 
3.9 0.30 
3.9 0.15 
3.9 0.075 
r 
M• I • J..r,no.l. 
0. 0175 
o. 0175 
o. 0175 
o.or5 
I 
Ag Sulfadiazine 
0.10 
0.10 
0.10 
0.10 
1.!], ·1 ~· ;;Tr ·!, • 
'I I I I Ill 
~ 
0 
. .u . .': 
', 
i 
TABLE XI 
Gross Physical Appearance (GPA) of Additional 
Nitrofurazone Formulas Before and After Storage' 
Formula GPA on Day of Gross Physical Appearance After ~Storage in I 
No. Preparation 
Freezer Refrigerator Dessicator Oven Room 
(-'5°; R.H. 75-90%) (+5°; R.H. 55-60%) (22 °; R.H. 5-6%) (37°; R.H. 25%) (22°; R.H. 45!',,) 
I 
I Flexible Increased porosity Unchanged Loss of Totally Same as I in 
Dissolved on moist Other properties flex~bility deteriorated I dessicator 
skin in 15 sec. unchanged I Other properties 
I 
J 
Not sticky unchanged 
Even porosity 
v Flexible Increased Same as V in Loss of Totally S2,me as V in i 
Dissolved on moist stickiness freezer flexibility deteriorated dessicator I 
I skin in 15 sec. Slight increase Great increase 
I 
Less sticky than in porosity in porosi-ty 
II-IV Other properties Stuck to bags 
Even porosity unchanged Other properties i 
unchanged I 
I VI Very flexible Unchanged tin changed Same as V in I Totally Sarr.e as V at 
Dissolved on moist dessicator deteriorated room 
skin in 15 sec. I Less sticky than 
II-V I 
Even porosity I 
! i VII Very flexible j Unchanged Unchanged Very slight loss Totally Same as VII I Dissolved on moist 
1 
of flexibility l 
skin in 15 sec. deteriorated in dessic. [ Other properties I Not sticky . unchanged 
Even porosity I i I ! ..;::-
, r:wm~~r "1~11111'1 'I I I' . ···r I r:rn Ill 
::.-u. :iJ' 
'" . .!1 
Formula 
No. 
GPA oilDay of 
Preparation 
TABLE XII 
Gross Physical Appeara~ce (GPA) of Additional Silver 
Sulfadiazine Formulas Before and After Storage 
Freezer 
(-5o; R.H. 75-90%) 
Gross-P:tlysicar Appearance After 
Refrigerator 
(+So; R.H. 55-60%) 
Dessicator 
(220; R.H. 5-6%) 
~~age~ 
I . 
Oven I 
(370; R.H.25%)i 
I I Flexible 1 Unchanged Unchanged Slight loss of Totally I Dissolved on moist flexibility deteriorated II 
I. skin in 15 sec. Other properties 
1 
! 
en porosity 
Roor.1 t 
(220;R.H. 45%)1 
I 
Unchanged 
~t sticky unchanged . V I Very flexible Unchanged Unchanged I Loss of Totally I Unchanged I 
Dissolved on moist flexibility deteriorated 1 •
1 
skin in 15 sec. Great increase !I 
Less sticky than in porosity . 
II-IV Other properties l I I 
Even porosity unchanged j ... 
. VI I Very flexible Unchanged Unchanged Same as V in II To'tally j Sa:ne as V in ' 
I Dissolved on moist dessicator deteriorated dessicator· skin in 15 sec. I 
I
• Less sticky than 
II-V . 
Even porosity I ~ j 
l VII I v:ry flexible . Unchanged Unchanged I Sa:ne as I in I Totally .I! I 
I Dlssolfed on molst dessicator ! deteriorated skin in 15 sec. 1 
1
1 
• I 
Not sticky I I Even porosity I ! I 
I 
Unchanged 
~ 
: J:[m~::":rr:i~n 'I ··' T I· 1~1 '····'I J'.ll r·rr::'· '·'"IT I . Ll'o!L.I.I..I ... 
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caused the dry foam to be too sticky such that it could not be easily 
handled. In a concentration of 0.19%, i.e., formula VII, the dry foam 
was very similar to the original, but because it was felt that glycerin 
would decrease the tendency to Jose moisture and thus, increase the 
chances of maintaining flexibility, formula VI I was chosen for further 
eva 1 ua t ion . 
From these preliminary tests, a three month storage study was 
dry foams packaged in foil laminates and stored in a freezer, refrigera-
tor, dessicator, and at room temperature. Storage at elevated 
temperatures much greater than room temperature were not satisfactory, 
regardless of the package or the formula. Also, the preliminary studies 
indicated that laminated aluminum foil bags fulfilled the moisture ~-
impermeable requirements (see Tables XI and XI 1). However~ because of 
the unavailability of the original foil bags, another type had to be 
obtained. This change was not considered significant since all laminated 
aluminum foils are considered impermeable to moisture. Thus, different 
laminated aluminum foil bags were secured from the Rexham Corporation; 
these new bags, starting from the inner side, consisted of a paper/ 
primer/polyethylene/.001 11 aluminum foil/vinyl wash/resin coating. 
Procedure for Nitrofurazone 1% Dr~~ 
The following formula was prepared: 
Dextran 16.00 g 
Sorbitol 10.40 g 
Glycerin 0.20 9 
Mi ranol 0.20 g 
Nitrofurazone 
Water 
0.27 9 
75.80 9 
44 
The identical procedures previously described for manufacturing, moisture 
content determination, and packaging were followed. Calculations for 
determining the amount of active ingredient needed were done on a dry 
weight basis using 10% as the average moisture content. The average 
moisture content of ten samples on the day of manufacture was found to 
A drug product must be both physically and therapeutically 
stable. Moisture content mainly affects the physical properties of the 
dry foam; to determine if storage conditions, packaging material, and/or 
time affected the therapeutic efficacy, in vitro release using a modified 
agar plate method was done. Antibiotic Medium 2 was made according to 
the manufacturer's directions, autoclaved at 15 psi and 121° for 30 
minutes. Twenty-five ml were then poured into 15 x 100 mm disposable 
petri dishes. The agar was allowed to gel and ten plates were seeded 
with 0.1 ml of an overnight inoculum of _Staphyl_ococcus aureus A.T.C.C. 
#25293. Two sterile penicylinders were placed on the gelled agar plates; 
one was filled with approximately 0.3 g of Furacin Cream 0.2% and the 
other, with Unibase to serve as a control. One disc of the freshly made 
dry nitrofurazone foam was placed on each of the ten plates. The plates 
were incubated at 37° for 24 hours following which ~he zones of inhibi-
tion were read, using the Fisher-Lilly Zone Reader. 
At monthly intervals, for a period of three months, four samples 
of the dry foam were removed from each storage condition and moisture 
content determined. Also, one sample from each condition was removed 
and in vitro release was determined using the above procedure. 
~= 
~-
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Preliminary work with nitrofurazone indicated that 0.2% nitro-
furazone dry foam did not give equal or greater zones of inhibition than 
the commercial cream. Prob~bly, this was not because the foam did not 
release the drug, but simply because there was much less nitrofurazone, 
i.e., subtherapeutic concentrations, per disc of foam than in 0.3 g of 
Furacin Cream. Therefore, the concentration of nitrofurazone in the 
foam had to be increased to provide therapeutic concentrations. Table 
XIII summar-izes the average zones of inhibition from ten readings 
obtained with varying concentrations of nitrofurazone. One percent was 
selected as therapeutically equivalent to the commercial cream. 
Results for nitrofurazone dry foam for moisture content and in 
vitro release on the day of manufacture and at one month intervals of 
storage are listed in Tables XIV and XV. Each sample shown in the 
tables was taken from its own foil bag. 
Procedure for Silver Sulfadiazine 1% Dry Foam 
The following formula was manufactured: 
Dextran 
Sorbitol 
Glycerin 
Hirano 1 
Silver sulfadiazine 
Water 
16.00 g 
10.40 g 
0.20 g 
0.20 g 
0.27 g. 
75.80 g 
The identical procedure described for nitrofurazone dry foam was employed 
for silver sulfadiazine with respect to preparation, moisture content 
calculations, and determination of a suitable package and of proper 
storage conditions .. Average moisture content of ten samples of silver 
6;--
= 
r 
TABLE XIII 
Zones of Inhibition Obtained vdth 
Various Concentrations of Nitrofurazone 
Drug 
Furacin Cream 0.2% 
Nitrofurazone Foam 
Nitrofurazone Foam 
Nitrofurazone Foam 
Nitrofurazone Foam 
Nitrofurazone Foam 
Nitrofurazone Foam 
Control~·: 
0.2% 
0.5% 
0.75% 
1. 0% 
2.0% 
3.0% 
Mean Diameter (rom) 
(average of 10 readings) 
12.1 
not distinguishable 
.6.4 
10.9 
12.9 
14.3 
19.7 
o.o 
* Unibase, Parke-Davis Co., Detroit, Mich. 
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TABLE XIV 
l1oisture Content (%) of 1% Nitrofurazone Dry Foam 
on the Day of Preparation and After Storage 
Sa.11ple I Day of One Month's Storage .,,o Months' Sto~ge l Three Months' Storage t 
No. Preparation 
A B c D A B C D A B c D 
1 9.8 8.8 9.2 9. 61 7.4 9.4 9.5 9.6 7. 7-, 8.41 8.7 9.7 9.0 I 
2 10.2 I 10.8 9.7 9.3 6.0 9.8 9.5 9.7 9.9 9.3 9.4 10.2 4.6 I 3 9.6 8.6 10.1 9.1 7.8 10.0 10.0 9.6 8.9 12.6 9.6 9. 51 7.5 
' 
l 
4 10.8 9.6 9.4 9.7 7_.2 9.5 9.7 9.1 7.0 9. 31 9.0 10.3 9.6 I 5 10.4 I I I I I I 6 9.3 I ! 7 8.8 I I 
I I ! 8 9.4. I ' 9 8.8 I I 10 9.8 I 
9. sl i ME&~ 9.7 9.5 9.4 9. 71 7.1 9.7 9.7 9. s 1 8.4 · 1 
I 
9.2 1 9.91 7.7 I 
< .7 <.5, 
>.9 J 
I I I I 
<.9 <. 7 <·OS <. sl <. 2 < . 7 I<. 02 I p~·· >. 9 I > .5 >· 7 > . 3 I <. oo1 :>.5 >.02 > . 7 > .1 > . 5 i >. 01 I ! i I 
A= 220; R.H., 47-51% 
B =+5°; R.H., 55-60% 
~ 
:u 
: ~~~;: ·~~:irln ,L , 1 • r 1 . I i.JI :1 ll 
I 
I 
I 
I 
Plate Day of 
No. Preparation 
Cr Foam 
1 ? 11.9 
2 9.0 9.5 
3 10.2 9.8 
4 i 10~1 9.6 
5 9.9 9.4 
6 10.6 10.8 
7 I 10.6 10.5 
8 10.3 11.6 
9 9.5 11.0 
11'1 11.6 11.5 
MEAN 10.2 10.6 
Cr 
9.4 
8.6 
9.9 
9.3 
10.0 
9.3 
9.3 
12.5 
9.6 
TABLE XV 
Diameters (rnm) of Zones of Inhibition of 0.2% Nitrofurazone Crei3.m and 
1% Nitrofur=ne Dry Fo"' on the Day of Preparation and After sforage 
One Month 
11 
Two Months 
A B c D I I Cr A B c D Cr 
11.2 10.7 10.0 10.1 9.3 11.7 10.71 12.6 9.6 9.8 
9.6 11.3 12.9 ' 9. 7 10.7 11.7 11.41 10.0 11.2 11.2 
10.8 12.0 11.2 9.4 9.5 10.0 10.1 10.6 10.1 10.1 
11.9 10.5 11.0 9.5 8.2 9.6 11.41 10.7 9.8 11.0 
9.8 12.1 11.3 10.0 10.2 10.5 12,0 11.8 9.4 11.5 
10.3 12.3 12.1 10.3 11.1 11.8 12.3 10.3 10.2 9.9 
9.9 11.7 10.4 8.9 10.0 12.5 12.0 12.6 10.8 10.5 
12.6 13.4 13.1 12.71 9.4 12.3 . 11.9 13.2 10.5 
10.1 1:1.1 11.0 11.3 12.8 12.2 :11.6 10.2 9.9 ~~:~II 
10.41 
I 
11.11 11.3 9.7 10.5 9.9 12.5 13.0 10.6 12.8 10.6 
' 9.8 10.7 11.6 11.3 10.1 9.9 11.5 11.7 11.4 10.611 10.5 
p1 ~2 p3 p3 p3 p3 p2 p3 p3 p3 p3 I p2 < .5 . s I <.9 < .05 < .2 < .3 < .5 < .1 < .02 < .2 
'> . 9 I <-5 >.3 • 3 I >· 7 > .02 > .1 > .2 >.3 >.05 > .01 > .1 > .3 
--· 
-~ 
--
I I 
A= 22°; R.H., 47-51% P 1 - Student t; crea."'ll vs. foam on day of preparJ.tion 
B = +5°; R.H., 55-60% P2 - Student t; cream vs. cream after storage 
C = -5?; R.H,~- 75-90% ~3 - Student t; foam ys. foam after storage 
D = 22~; R.f{.~ 5-6% 
, mNrn~r i rn~n ' I 
Three Months :i 
A B c D 
13.11 11.4 12.8 12.0 
14.0 13.0 13.0 12.8 
12.5 11.4 11.8 12.0 
12.5 12.2 12.1 12.1 
12.5 13.8 11.2 13.5 
12.3 12.8 12.2 11.8 ' 
12.7 12.7 12.6 13.4 
13.8 10.61 12.9 11.9 
12.7 11.5 12.81 14.0 
13.11 I 14.1 12.51 12.1 
13.0 12c2 12.5 12.6 
?3 p3 I p3 p3 I t 
(.001 < .01 < .001 I > .001 < .001 
I 
-t::-
c:> 
Uli :.:u: 
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sulfadiazine dry foam on the day of manufacture was found to be 9.8%. In 
vitro release was compared to the commercially available silver sulfadla-
zine 1% cream. 
Results for silver sulfadiazine dry foam for moisture content 
and in vitro release on the day of manufacture and at monthly intervals 
of storage are listed in Tables XVI and XVI I. As with nitrofurazone, 
each sample shown in the tables for silver sulfadiazine was taken from 
its own fori-bag. 
Sterilization Procedures 
t1ethod I: 
Unmedicated casting solution, i.e., dextran, sorbitol, glycerin, 
Miranol, and water, was inoculated with 0.2 ml of an overnight inoculum 
of ~~~ and then autoc 1 aved at 15 psi and 121 o for 20 minutes. 
The resultant solution was placed in a sterile bowl in a laminar flow 
hood and whipped with sterile beaters. The whipped foam was ascep-
tically spread onto sterilized pans and allowed to dry in the hood. 
t1ethod II : 
Unmedicated casting solution inoculated with 0.2 ml of an over-
night inoculum of S. aureus was filtered through a 0.22 micron 
Mi 11 ipore fi Iter into a sterile bowl. This was done in a laminar flow 
hood using a 50 ml syringe.· The solution was whipped with sterile 
beaters and aseptically spread onto sterile pans and allowed to dry in 
the hood. 
Hethod Ill: 
Unmedicated casting solution was inoculated with 0.2 ml of an 
--· 
·-.. ~W'>""'""'-'!n'--"'-"'' 
'rABLE XVI 
Moisture Content (%) of 19,; Silver· Sulfadiazine Dry Fo ·~ 
on the Day of Preparation and After Storage 
-
Sample Day of .One Month's Storage I Two Months' Storage I Three Months' Storage No. Preparation I A B c D I A B c D A B c D 
I I 9. ~r 1 9.8 8.1 8.8 9.5 8.8 9.5 9.8 10.2 9.0 9.6 9.4 5.8 
2 10.7 9.2 10.2 9.5 8.5 9.1 10.3 9.7 9.B 9.3 10.7 9.4 10.3 
I I 3 9.1 8.9 8.4 10.0 9.8 9.2 10'.1 10.2 12.5> 8.5 9.4 9.5 8.6 I 10.4 I I .., 4 9.2 9.7 9.9 11.3 9.1 9.5 9.8 10.8 9.9 9.9 9.3 9.9 5 9.9 I 
6 1LO 
7 9.2 
8 10.2 I I 
9 9.3 
) l I 10 9.1 I I 
MEAN 9.8 9.0 9.3 10.1 9.1 I 9.3 10.2 10.0 10. s, ,, 9.2 9.9 9.4 8.7 I 
< ~ < .3 <. 7 < .5 <. 7 < .3 < .7 < ,.1 < .2 <:.9 < .31 < .2 p:l< I .. • Ll :> .05 > .2 >.5 ";>.3 > .5 > .2 > .5 >.1 )'.1 >· 7 >.2\~·1 
"' Student t calculations comparing mqisture content on day of preparation with m::)isture content after storage 
I 1:w~r~' I • ' i. IT'IIJill~ ~. 
I 111 111111111:1 II .. II . I Ill' i. .:I 
J'.[L I 
I 
\.11 
0 
. u: ·, 
Plate Day of 
No. Preparation 
I Cr Foam 1 9.8 11.8 
2 10.8 10.6 
3 10.2 11.4 
4 9.4 12.2 
5 9.0 11.2 
6 9.4 12.1 
7 10.6 11.5 
8 10.0 10.9 
9 8.2 11.6 
10 10.8 '10. 8 
Mt:Ai''i 9.8 11.4 
p 
1 
I < .001 I 
-
0 A = 22 ; R.H., 47-51% 
B =+5°; R.H., 55-60% 
C =-5°; R.H., 75-90% 
D = 22°; R.H,, 5-6% 
·-~~·~•"c"'""~" '"'"'Jl -.__ 
TABLE XVII 
Diameters (mm) of Zones of Inhibition of 1% Silver Sulfadiazine Cl~eam and 
1% Silver Sulfadiazine Dry Foam on i:he Day of Preparation and AfteJ Storage 
I . 
One Month Two Months I 
I Cr A B. c D Cr A B c D Cr A 
' 
11.4 11.3 11.5 11.3 . 11.3 9.4 11.6 10.5 11.1 10.1 10.9 9.5 
9.7 14.3 15.0 15.5 13.0 8.7 12.4 10.0 12.5 10.6 9.8 10.1 
8.8 12.0 10.9 13.7 12.5 9.2 10.8 11.6 10.7 11.5 8.2 10.0 
10.5 9.8 9.6 10.8. 11.1 9.5 10.4 10.7 10.4 10.9 9.7,10.1 
9.3 10.4 11.6 12.2 12.2 8.8 10.4 11.8 10.3 11.8 9.3 10.2 
9.5,11.6 11.6 13.5 13.8 9.2 9. 91 12.4 11.0 9.1 'lo.o 9.8 
' 9.1 I 11.0 9. 7 9.7 11.0 10.5 9.1 10.51 11.8 12.0 9.4 10.6 
10.7 10~2 11.7 13.0 11.3 9.3 10.8 10.4 1.0. 9 10.7 i12.ol1o.o 
8.3 11.2 10.0 12.4 13.1 8.9 13.6 12.1 13.6 11.6 1 0.41 9. 9 
I I_ 9.1 11.1 10.1 10.6 11.0 8.9 11.9 13.2 11.4 12.5 ill. 5 11. 2. 
9.8 11.2 11.2 12.4 12.0 9.1 11.2 11.5 11.4 10.9 ~~0.1! 10.1 
p p p F p p p p p p p p 
2 3 . 3 3 3 2 3 3 3 3 2 3 
> .9 < .7 < .9 < .1 < .2 < .05 <..7 < .9 > .9 < .2 I,= ·7 <.001 > . 5 > . 7 > .05 > .1 > .02 ).5 ;. .7 > .1 
---~-- --~ - ---
-- '-----~ ~-~ ~--:t · 5 L__ _ 
I 
P 1 - Student t; crea1n vs. foam on day of pre par at :Lon 
P2 - Student t; cream vs. cream after storage 
P3 - Student t; foam vs. foam after.storage 
',mm~~:: "i,IT111n '. I 'll I 
Three Months 
B c D 
12.4 10.1! 10.0 
11.3 10.71 10.2 
11.5 10.0 11.5 
10.1 11.7 9. 7: 
10.6 10;2 10.5 
10.1 9.~ 10.1 
11:.61 11.1 10.4 
13.3 11.5 12.8 
12.5 10.3 11.1 
11.5 11.9 10.3 
11.4 10. s 1 10.7 
p l p p 3 3 3 
> .s' < ·'I< .1 I 
___ I >.os. >:_.os J 
\J"l 
'· 
L:IIn II. .. , I . - . ''I ~: .... .. '
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overnight inoculum of S. aureus and whipped in a bowl. The whipped 
foam was spread onto a pan and allowed to dry in a laminar flow hood. 
The dry foam was removed and placed in ethylene oxide permeable plastic 
bags obtained from Tower Products, Inc. The packaged foam was then 
placed in a cold cycle (29°) ethylene oxide chamber and the cycle 
allowed to run for three hours using 100% ethylene oxide. Spores of 
!!...:._subtil~were used as the biological indicator while lndox Ethylene 
Oxraerncn cator· served as the chemica 1 i nd i cat or. Upon comp 1 et ion of 
the cycle, both indicators showed that ethylene oxide sterilization 
requirements were met. The packaged foam was then aerated for eight 
hours at 63° in an aeration chamber to allow dissipation of ethylene 
oxide residues. 
t4ethod IV: 
Unmedicated casting solution was inoculated with 0.2 ml of an 
overnight inoculum of S. aureu~. The solution was whipped, spread 
onto pans, and allowed to dry as above. The contaminated dry foam was 
packaged in aluminum foil laminates provided by the Rexham Corporation 
and mailed to International Nutronics, lnc.,a a commercial radiation 
sterilizing company. Cobalt-60 was the source of the gamma radiation 
using a total dose of 2.5 t4rads. After sterilization, the packages 
were returned unopened to the laboratory for testing. 
Steri 1 i·ty Testing Procedures: 
Samples of dry foams sterilized by the four methods above were 
tested for sterility. The USP XVI II method using Fluid Thioglycollate 
a. International Nutronics, Inc., Palo Alto, Cal if. 
~ 
w--
~--
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Medium (FTM) and Soybean Casein Digest Medium (SCD) was employed. To 
two test tubes each of FTM and SCD were added samples from each method. 
The test tubes were allowed to incubate in an incubating oven for 14 days 
at 37°. Also, two positive controls, i.e., tubes of media containing 
0.1 ml of an overnight inoculum of S. aureus, and two negative controls 
were used for comparison. Samples of the contaminated dry foams prior 
to sterilization by ethylene oxide and radiation were added to additional 
~-------t~e-s~t~t~u~b_e_s--o'f~F~T~M--a-n'd~S~C~D-a_n_d.-'in_c_u'b-a~t--e-d.-w~i~t~h~t~h-e--o~t~h-e-r~te-s-·t~m_e_d~i~a-.~---------------_ 
Samples of the two aseptic preparation methods (Methods I and I I) 
were packaged in laminated foil bags and stored at room conditions for 
one month. The samples were then aseptically removed and tested for 
ster i 1 i ty. 
Miscellaneous Procedures: 
The most common defect with laminated aluminum bags is an 
ineffective seal. Thus, fifty bags were sealed with a heat sealer and 
totally immersed in water for twenty-four hours. Upon removal and open-
ing of the bags, none contained moisture indicating that the sealing 
procedure was effective. 
To determine if the dry foam could withstand normal shipping and 
mailing conditions, four samples of unmedicated, uncontaminated dry foam 
were packaged in laminated foil and shipped by mail to the East coast 
and returned unopened to the laboratory. The same p-eckages were sent 
immediately to a second West coast city and again returned unopened. 
These shipped samples were then compared to control samples from the 
same batch that were packaged and kept in the laboratory. 
CHAPTER I I I 
RESULTS 
Nitrofurazone StabilJJJL 
Table XIV summarizes the average moisture content of packaged 
three months' storage at four different storage conditions. As shown, 
the average moisture content of ten samples on the day of manufacture 
was 9.7%. 
After one month's storage in a refrigerator (+5°; R.H., 55-60%), 
freezer (-5°; R.H., 75-90%), and at room conditions (22°; R.H., 50%) the 
changes in moisture content were statistically insignificant with the 
largest change, i.e., 9.7% to 9.4%, occurring in the freezer. The 
insignificance of these small changes in moisture is not only shown 
statistically, but also reflected by the fact that, in all cases, the 
nitrofurazone dry foam retained its flexibility, porosity, and nonsticki-
ness. However, when stored in a dessicator (22°; R.H., 5-6%) for one 
month, the moisture content dropped from 9.7% to 7.1% (P < .001) and the 
foam became very friable. 
After two months' storage in a refrigerator and at room conditions 
with an average relative humidity of 47%, no significant changes in 
moisture content and gross physical properties were noted. A drop to 
9.5% moisture content occurred in the freezer, but again, this was 
n~lible as the foam still possessed the ideal characteristics. In the 
dessicator, the moisture content dropped from 9.7% on the day of 
~--
-
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manufacture to 8.4% (P > .02 < .05) causing the foam to lose its flexi-
b i 1 i ty. 
No changes in physical properties occurred after three months' 
storage in the refrigerator, freezer, and at room conditions (R.H., 48%) 
despite the fact that the moisture content of the foam in the freezer 
and at room temperature increased to 9.9% while it decreased to 9.2% in 
the refrigerator. These changes are statistically insignificant. Againt 
dessicator with subsequent loss of flexibility. 
Table XV lists the zones of inhibition obtained with nitrofura-
zone dry foam on the day of manufacture and after one, two, and three 
months' storage at each of the four storage conditions. Also included 
in the table are the zones of inhibition obtained with the commercially 
~vailable nitrofurazone cream. Storage of the nitrofurazone dry foam at 
room conditions, a freezer, and a dessicator for one and two months did 
not produce statistically different zones of inhibition from the zones 
produced on the day of manufacture. Samples stored in a refrigerator 
for one and two months did, however, produce statistically different 
zones as did storage for three months at all four conditions. These 
statistically significant diameters of zones after storage were all 
greater than those on the day of manufacture. 
Silver Sulfa~iazine Stability 
' 
Table XVI summarizes the average moisture content of packaged 
silver sulfadiazine dry foam on the day of manufacture and after one, 
two, and three months' storage at the four different storage conditions. 
The average moisture content from ten readings on the day of manufacture 
~-
~-------- ------------- --
A drop in moisture content from 9~8% to 9.0% was noted in the 
samples stored at room conditions for one month; a slight increase in 
porosity occurred, but flexibility was sti 11 maintained. In the refrig-
erator and freezer after one month, the silver sulfadiazine samples all 
retained their original physical propertie~ despite slight changes in 
moisture content. The samples stored in the dessicator for one month 
demonstrated a I os s of mo 1 s ture con tent from 9--:-8% to 9--:-r%; a s Hght 
increase in porosity was noted, but flexibility was still maintained. 
',,..y 
Statistical evaluation showed that these changes were all insignificant. 
After two months• storage, all the samples under all the storage 
conditions retained their original gross physical properties. The 
samples at room conditions had a drop in moisture content from 9.8% to 
9.3% while the samples in the refrigerator, freezer, and dessicator all 
gained moisture from 9.8% to 10.2%, 10.0%, and 10.6% respectively. 
Again, these changes were statistically insignificant. 
Samples stored for three months at room conditions and in the 
freezer lost slight amounts of moisture but demonstrated no changes in 
physical properties. After three months in the refrigerator, again the 
-
samples retained their physical qualities despite a slight increase in 
moisture content to 9.9%. Samples in the dessicator lost slightly more 
than 1% moisture but still possessed adequate flexibi)ity although they 
exhibited a relatively large increase in porosity. These moisture con-
tent changes were all statistically insignificant. 
Table XVI I gives the zones of inhibition obtained with silver 
sulfadiazine dry foam on the day of manufacture and after storage under 
conditions identical to those for nitrofurazone preparations. The zones 
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of inhibition given by the commercially available silver sulfadiazine 1% 
cream are also included in Table XVI I. No statistically significant 
differences were noted between the silver sulfadiazine dry foam zones 
obtained on the day of manufacture and after one, two, and three months 1 
storage regardless of the storage condition with one exception. After 
~-
three months at room conditions, a statistically smaller mean zone of 
inhibit1on was produced (P < .001). 
Results of Sterilization of Dry Foam 
Method 1: 
Sterilization of the inoculated casting solution by autoclaving 
did not produce any changes in its consistency and spreadability during 
the subsequent aseptic preparation of the dry foam. The final product ~-
also did ~ot show any physical changes. Samples of the dry foam so 
prepared did not show any growth on incubation in the two media used 
to test their sterility. The positive controls showed growth while 
the negative controls showed no growth. 
Method I I : 
Filtration of the inoculated casting solution also did not 
alter the c6nsistency and spreadabil ity of the whipped foam and/or the 
physical properties of the final product. Aseptic preparation of the 
dry foam produced a sterile product as no growth occurred after four-
teen days 1 incubation. Both negative controls of each medium also 
exhibited no growth while the positive controls did. 
Samples of dry foam prepared by Methods I and I I above and 
aseptically packaged in laminated aluminum foil were tested for 
~~~~- ~ ~ ~~~ ~ ~ --~----------
sterility after storage for one month at room conditions. These 
samples also showed sterility despite the fact that the insides of the 
foil packages were only cleaned by wiping with 70% isopropanol (rubbing 
alcohol). 
11ethod I II : 
Samples of inoculated dry foam prior to ethylene oxide sterili-
zation showed growth in the media used. Separate samples of foam after 
ethylene oxide sterilization showed sterility. However, after the 
sterilization-aeration cycles were completed, the foam showed physical 
deterioration such as Joss of flexibility and increase in porosity. 
Method IV: 
The irradiation sterilized samples of dry foam also met the 
test for sterility. Freshly inoculated samples prior to sterilization, 
as expected, showed growth. Some loss of flexibility of the foam 
after irradiation sterilization was observed. However, this loss was 
not significant enough to affect the desirable features of the product. 
Results of Shi~~ 
Comparison of the shipped samples and controls kept in the 
-
laboratory showed that there was no loss of desirable features of flexi-
bility and porosity on shipping. 
CHAPTER IV 
DISCUSSION 
Conventional topical dosage forms consist of solutions, lotions, 
creams, oir{tments, and aerosols. While these types of products are 
~-
~-
widel used, they are not without some inherent_d_i_s_ad_v_ao_t_a_ge_s_s_ucb_as. ______ _ 
necessity for removal, waste especially from aerosols, and possible 
aggravation of open lesions vfa inunction. Because of thes~ disadvan-
tages, a novel topical dressing which would dissolve on moist skin, 
release the active ingredient without inunction, and not necessitate 
removal was developed (1-3). However, this dressing had its own 
disadvantages; the most significant being loss of moisture and flexibility 
prior to and during storage. Therefore, the use of a moisture impermeable 
package and determination of suitable storage conditions were necessary. 
Because of the inexpensiveness and great versatility of plastics, 
a twelve week storage study was designed using what was thought to be a 
moisture proof plastic bag (see Table I I 1). After twelve weeks of 
storage in a refrigerator with periodic evaluation of moist~re content, 
it was found that the dry foam gained moisture and became very sticky 
and difficult to handle. In a freezer, the foam liquified completely in 
just four weeks. Storage at room conditions produce'cl very inconsistent 
data. An increase in moisture content occurred after two and three 
weeks' storage while a decrease occurred after four weeks. Similarly, 
six weeks' storage showed increased moisture content while eight and 
twelve weeks' caused decreased moisture content. These room condition 
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samples maintained good flexibility without acquiring a tacky feeling. 
The results of this study confi~med that the dry foam was sensitive to 
moisture and indicated that the plastic bags were permeable to moisture. 
Consequently, a four week storage study employing plastic bags 
lined with waxed-paper and parchment paper as well as double-bagging was 
initiated to determine if these liners or double thickness bags would 
minimize moisture permeation (see Table IV). With waxed-paper or double 
bagging, moisture content dropped sufficiently to cause loss of flexi-
bility in samples stored at room conditions; samples packaged with 
parchment liner also lost moisture, but flexibility was maintained after 
one, two, three, and four weeks. All samples stored at 3r lost moisture 
and flexibility regardless of the type of 1 iner or double bagging, even 
.after only one week of storage. Freezer samples, again regardless of 
the type of package, gained sufficient moisture after three and four 
weeks to cause tackiness such that the foam could not be easily handled; 
samples stored in a refrigerator all maintained adequate flexibility 
without tackiness after four weeks. 
One would expect that if the foam gains or loses moi~ture at a 
particular storage condition, such a change would be steady and con-
-
sistent. That is, if a gain were noted after one week storage, then a 
drop in moisture after two or three weeks should not occur. However, 
this was not the case, especially a~ room conditions. These inconsistent 
data (see Tables I II and IV) indicated that some other factor besides 
temperature and type of package was also playing an important role in the 
physical stability of the foam. This factor was finally determined to be 
relative humidity which, of course, changes from time to time, not only 
at room conditions, but also in refrigerators and freezers. Although 
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Tables I II and IV indicate relative humidity at the various storage 
conditions, this was not monitored during these two preliminary studies 
because It wasn•t anticipated that relative humidity would be a signifi-
cant factor. 
These results showed that 1) the plastic bags· ·were permeable, .2) 
~-
both temperature and relative humidity during storage must be controlled, 
and 3) the original formula might be improved to produce a more stable 
ry foam. As stated earlier, a significant drop in moisture content 
would cause a loss of flexibility while an increase may cause the foam 
to be too tacky. Of these two possibilities, loss of flexibility is the 
more important because an inflexible dressing cannot be applied to 
anatomical areas that have nonplanar geometry. Although a tacky product 
could be applied to body areas, its hand! ing may require forceps or it 
may adhere to the package. 
The loss of flexibility may be attributed to crystallization of 
sorbitol occurring on loss of water. Glycerin in varying concentrations 
was used as a second humectant and an adjunct to maintain sorbitol in 
solution, resulting in a more pliable foam. Packaging material other 
than plastic bags would also be required to maintain moisture content of 
the foam. Laminated aluminum foil was selected since it would be the 
most satisfactory moisture proof package. Consequently, foil laminates 
were used during the remainder of the study. 
Three different dry foam formulas containing nitrofurazone and 
silver sulfadiazine were manufactured, packaged in the foil bags, and 
stored for one week at the two extremes of relative humidity, freezer 
{R.H., 75-90%) and dessicator {R.H., 5-6%). These modified formulas are 
listed in Tables V and VI. Moisture content on the day of manufacture 
~~~~~ ~ ---------~----~ -
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and after storage as wei 1 as subjective comments regarding physical 
properties are summarized in Tables Vl1 and VI I I. Comparison of the 
three modified formulas with the original, showed that formulas II and 
I I I became very tacky after one week in the freezer, and exhibited a 
slight Joss in flexibility and an increase in por6sity in the dessicator. 
Formula IV, while less tacky than formulas I I and I I I, was more sticky 
than the original. After storage in the freezer, the tackiness of formula 
IV was relatively satisfactory, but not ideal. Both the original formula 
and formula IV showed slight losses of flexibility and increases in 
porosity after storage in the dessicator. Changes in physical properties 
would appear to be directly related to changes in moisture content. In 
fact, this was the major assumption and reason for finding a moisture 
impermeable package and for defining exact storage conditions with ~-
respect to relative humidity and temperature. However, study of formulas 
II through IV showed that this was not the entire picture, but that 
factors other than moisture content also cause physical changes on 
storage. Formulas I I-IV as well as the original formula did not gain or 
' lose significant amounts of moisture when packaged in foil and yet, they 
exhibited unsatisfactory changes in physical properties. To explain 
these changes is difficult, but they apparently are inherent in the 
formula. 
Because formulas I I-IV exhibited unsatisfactqry physical changes, 
additional formulas, V-VI I, with decreasing concentrations of glycerin 
were prepared. These additional formulas are listed in Tables IX and X. 
They were evaluated for physical properties on the day of manufacture 
and then packaged in foil and stored for one week at room conditions, in 
a freezer, a refrigerator, a dessicator, and an oven set at 37°. Because 
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the previous study showed that the foil bags were very satisfactory in 
preventing moisture content changes, the purpose of this work was only 
to find a more suitable formula that did not possess the unknovm, 
inherent factors alluded to earlier. A more suitable formula would be 
~= 
defined as one yielding a nonsticky, flexible product just as the 
original but which also contained some glycerin to help maintain flexi-
bility. The tackiness of formulas I I-IV was caused by excess glycerin. 
A-formu iaw1Tnfhe correct concentration of g 1 ycer in may not possess 
this unde5irable tackiness while it might retain greater flexibility than 
the original, nonglycerin formula. Tables XI and XI I summarize the 
physical properties of the original form~la and the additional modified 
formulas V-VII. Formulas V and VI showed simi Jar results as formulas 
II-IV; that is, too tacky in the freezer and loss of flexibility in the 
dessicator. All the formulas were totally deteriorated in an oven 
environment and exhibited varying changes in the refrigerator and at room 
conditions .. Of all the formulas, formula VII, i.e., the formula with the 
least amount of glycerin, was most satisfactory on the day of manufac-
ture as well as after storage at the various conditions excepting the 
oven. For this reason, it was chosen as the most suitable formula for 
further evaluation. 
The preliminary work indicated that laminated aluminum foil bags 
appeared to be a suitable package, that temperatures ~bove room tempera-
ture caused physical rnstability of th~ packaged foam, and that a Joss 
of flexibility was not always associated with losses in moisture content. 
Also, preliminary studies indicated that proper storage conditions must 
be defined in terms of relative humidity as well as temperature. 
As discussed earlier, a stable product must maintain potency and 
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' utjlity after it has been packaged and stored for prolonged periods. To 
determine the stability of the foam as far as shelf~life and marketing 
potential were concerned, a three month storage study was conducted with 
stability evaluated at one month intervals according to physical 
properties, moisture content changes, and potency as determined by the 
semiquantitative microbiological assay. 
On the day of manufacture, nitrofurazone foam was very flexible, 
not sticky, and dlssoived on moist skinwitnTn-fTfteen seconds; these 
properties make it a very useful dressing for traumatized and infected 
skin. On the day of manufacture, moisture content was 9.7%. After one, 
two, and three months' storage in a refrigerator, freezer, and at room 
conditions, the moisture content varied insignificantly (P > 0.3) and 
the foam retained its original physical properties. However, in a 
dessi~ator, the moisture content decreased significantly (P < .05 > .001) 
and the foam lost flexibility. The data in Table XIV show that the pack-
age is a suitable container for storage at high humidities as it 
prevented the foams from gaining excess moisture which would have caused 
them to become too tacky and difficult to handle. At low humiditi~s, 
however, the package did not prevent the foam from losing moisture. 
Preliminary work showed some formulas wi 11 lose flexibi 1 i ty without a 
corresponding decrease in moisture content, suggesting that some unknown 
inherent factors lrJere causing the foam to lose flexibility. However, in 
this three month study, the loss of flexibility was associated with a 
significant loss of moisture; this indicates that the modified formula, 
i.e., VI I, does not in itself contribute to loss of flexibility. Why 
th~ moiiture impermeable foil bags were not effective in preventing loss 
of moisture is elusory. Speculation would lead one to believe that 
,_; 
~-
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either the seals were ineffective or that the foil bags are not really 
impermeable. Because the sealing procedure was shown to be effective 
and samples stored at high humidities did not gain moisture, these 
speculative reasons can probably be eliminated. In general, the only 
~--
conclusion one can make frtim these data is that a relative humidi~y bf 
S-6% Will cause nitrofurazone dry foam to lose moisture and flexibility 
even when packaged in foil laminates. 
To determine if the storage conditions, time, and/or the package 
caused any deterioration of the drug in the foam or to determine if the 
vehicle itself inactivated the drug, a microbiological assay was done. 
A product must retain at least 90% of the labelled potency after storage 
for prolonged periods if it is to be accepted as therapeutically 
efficacious. Table XV shows the zones of inhibition both for the nitro·· 
furazone foam and the commercially available nitrofurazone cream obtained 
on the day of manufacture and after one, two, and three months 1 storage 
at the four storage conditions. Storage of the nitrofurazone dry foam 
at room conditions, freezer, and a dessicator for one and two months did 
not produce statistically different diameters of zones from those 
produced on the day of manufacture. Samples stored in a refrigerator 
for one and two months, however, did produce statistically different 
zones as did storage for three months at alI four conditions. These 
statistically different zones after storage were alI greater than those 
on the day of manufacture. To explain these differences is difficult 
although two possibilities exist. One is that refrigeration conditions 
or long storage causes some interaction to occur between nitrofurazone 
and one of the components of the vehicle (e.g., Miranol) such that a 
greater release occurs; What this interaction might be cannot be 
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ascertained at this time. However, when comparing differences between 
zones after one and two months with zones after three months, there is 
no significant difference and this fact casts a doubt on the possibility 
of an interaction resulting in increased release. The second explana-
tion involves the manufacturing process. All the samples were from the 
same .batch, but not necessarily from the same pans. Because some pans 
became slightly warped from use, a difference in the thickness of the 
foam between pans and even within the same pan may have occurred; also, 
differences in bubble size may have occurred since it was not very easy 
to obtain a consistent and uniform spreading procedure. Thus, samples 
which were thict<er or had small bubbles would have contained more active 
ingredient and produced larger zones; similarly, thinner samples or 
samples with larger bubbles would produce smaller zones. This second L_ ~-
possibility seems much more likely to explain the statistical differences 
observed with the nitrofurazone dry foam. 
On the day of manufacture, silver sulfadiazine foam was also 
very flexible, not sticky, and dissolved nn moist skin in fifteen 
seconds. Table XVI summarizes the moisture contents on the day of 
manufacture and after one, two, and three months 1 storage at the four 
storage conditions. Silver sulfadiazine dry foam packaged in laminated 
aluminum foil bags and stored for three months in a freezer, refrigera-
tor, and at room conditions showed similarities with nitrofurazone foam; 
... 
that is, physical properties and moisture content demonstrated 
statistically insignificant changes after one, two, and three months 1 
storage. Storage in a dessicator produced surprisingly interesting 
results. It would be expected from the nitrofurazone results that the 
silver sulfadiazine stored in a dessicator would also lose moisture and 
67 
flexibility. However, this was not the case at all; after one, two, and 
three months' storage, moisture content was statistically unchanged and 
flexibility was maintained. Because identical procedures with respect 
to manufacturing) packaging, storage, and evaluation were employed for 
both the nitrofurazone and silver sulfadiazine dry foams, the different 
results can only be attributed to the active ingredients- namely that 
silver sulfadiazine somehow aids in retaining moistu;·e and flexibility 
while nitrofurazone do~s not. Other active ingredients may very well 
exhibit similar types of effects and this must be considered during any 
future drug evaluations. 
As with nitrofurazone, potency as a guide to stability of silver 
sulfadiazine dry foam, was determined by comparing the zones of inhibition 
on the day of manufacture and after one, two, and three months' storage. 
Tab 1 e XV II shows the zones for both the foam and the commercia 11 y ava i 1-
able cream. Samples stored for one and two months at all four conditions 
produced zones of inhibition which were statistically insignificant from 
the zones obtained on the day of manufacture. Three months' storage in 
a refrigerator, freezer, and dessicator also did not affect the potency 
of the dry foam while samples stored at room conditions for three months 
produced statistically smaller zones (P < .001) when compared to the day 
" 
of manufacture. While the possibility that three months' storage at 
·room conditio~s could have caused a loss of potency, this difference was 
more likely due to variations in sample thickness and/or bubble size as 
discussed earlier. 
For use on open, infected lesions, use of a sterile product is 
desirable. Sterilization of the dry foam could easily be achieved by 
three of the four methods employed. Aseptic methods produced a sterile 
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product substantiated by no growth in the two accepted test media, fluid 
thioglycollate medium and soybean casein digest medium. Growth occurred 
in the positive controls which indicated that the media and incubation 
conditions were conducive to microbial growth. Because aseptic prepara-
~-
tion requires strict adherence to technique procedures and is always 
subject to accidental contamination, even if good technique is employed, 
sterilization of the final, packaged product is more advantageous from a 
manufacturer's viewpoint. 
Ethylene oxide is widely used to sterilize products which cannot 
be autoclaved and which can be packaged in ethylene oxide permeable 
containers, namely plastics. Even though this product must be packaged 
in foil, it could be packaged first in plastic, exposed to ethylene 
oxide, and then packaged as a double bag with a laminated aluminum foil 
bag as the outer container. For this reason, contaminated foam was 
packaged in plastic and sterilized in a cold ethylene oxide cycle, i.e., 
~-
29° for three hours, followed by aeration for eight hours at 63°. Upon 
removal of the foam, it was noted that all. flexibility was lost; the 
product was friable and crumbled easily. It was felt that this was due 
to the temperature employed in the aeration cycle and not due to a direct 
ethylene oxide chemical reaction. Even though sterility was achieved as 
shown by no growth in the testing media, the deteriorating effects of 
the ~eration cycle excludes ethylene oxide as a method of sterilizing 
this product. 
Method IV, gamma irradiation, is the method of choice for products 
packaged in laminated aluminum foil. Packaged samples which were exposed 
to radiation conditions were indeed rendered sterile as no growth was 
noted in the testing media; just as important was the fact that the foam 
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retained adequate flexibility and ~tility. Thus, this method provides a 
very practical, inexpensive, and efficient means to sterilize the 
packaged dry foam. It should be mentioned that all the methods of ster-
ilization were performed ~n unmedicated samples. Thus, radiation will 
not be a useful method if the drug or drugs incorporated into the foam 
are destroyed or undesirably altered by radiation. 
In order to determine if the foam could withstand normal shipping 
East Coast and returned unopened to the laboratory. The same packages 
were sent immediately to a second West Coast city and again returned 
unopened. These samples which were exp6sed to common mail handling were 
opened and compared to samples kept in the laboratory. No adverse 
changes were noted in the shipped samples as they alI retained their 
original flexibility and in general, showed that the product could very 
satisfactorily withstand any conditions of shipping and mailing. 
-
CHAPTER V 
SUMMARY AND CONCLUSIONS 
A highly water soluble, flexible dry foam was recently developed 
(1-3). The dry foam dissolves quickly on moist skin and releases the 
active ingredient without inunction. HQw_eiLe_r_,_tbe_£oam_Ls-sens-L1.:.-i-~e-to'---------c 
moisture such that a loss of moisture causes the foam to lose flexibility 
while a gain causes it to adhere to the package or liquefy when touched. 
The objectives of this study were to 1) modify the formula to 
minimize moisture sensitivity, 2) determine a suitable package, 3) 
determine proper storage conditions, 4) determine shelf-life of nitro-
furazone and silver sulfadiazine dry foams, and 5) det.ermine a suitable 
sterilizing procedure since the dry foam is intended for use on open, 
infected lesions. 
Six different modified formulas were made and compared to the 
original. Glycerin, in varying concentrations, was used as the modify-
ing agent since its humectant properties would help retain moisture and 
hence, flexibility. Comparison of the six formulas showed a glycerin 
concentration of 0.19% wet weight produced the most satisfactory dry 
foam with respect to flexibility, nonstickiness, dissolution time, and 
porosity. Using this modified formula, the remaining objectives were 
accomplished. 
Plastic bags and plastic with liners proved unsatisfactory as a 
packaging material as they were permeable to moisture. On the other 
hand, samples of dry foam packaged in laminated aluminum foi 1 bags and 
~-
·--~--~--~~~~~-~-
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stored at room conditions, in a refrigerator, and in a freezer, did not 
gain or lose moisture. However; aluminum laminates did not prevent loss 
of moistur~ and flexibility in samples sto~ed at elevated temperature, 
i.e., 3r,or low humidities, i.e., 5-6%. Because the latter storage 
conditions are impractical, the unsatisfactory results are only academic. 
Consequently, laminated aluminum foil bags provide a suitable packaging 
material for the dry foam. 
Wnrie storage at room conditions and in a freezer indicated the 
dry foam was physically stable for at least three months, refrigerat1on 
conditions appeared to be most satisfactory. Both temperature and 
relative humidity will physically alter the dry foam and these parameters 
can best be controlled in a refrigeration environment. Thus, 5° with a 
relative humidity of 55-60%, the usual refrigeration conditions, are 
recommended for storage of the dry foam. 
The study also indicated that the foam can physically withstand 
common shipping and mailing procedures; thus, mailing of the final 
product does not pose any problems. 
Potency of nitrofurazone and silver sulfadiazine dry foams was 
not significantly affected by any component of the vehicle, by the 
package, or by any of the storage conditions including the two extremes 
of relative humidity, 75-90% and 5-6%. Thus, at least.these two drugs 
can be incorporated successfully into the dry foam. This suggests that 
.... 
the dry foam might be a satisfactory vehicle for other commonly used 
antimicrobials. 
Sterilization with ethylene oxide causes the foam to lose 
flexibility and thus, this method cannot be used. While aseptic prepara-
tion employing autoclaving or filtration of the casting solution produced 
~-
--------------------
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a sterile product, the best method, with respect to expense, practicality, 
and efficiency, was sterilization by gamma irradiation. This method 
allows the final package~ product to be steri I ized without phys leal 
degradation. Gamma irradiation is therefore recommended as the steril-
ization procedure provided the active ingredients are not undesirably 
affected by radiation. 
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